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A B S T R A C T
Background
Oral squamous cell carcinoma is the most common form of malignancy of the lip and oral cavity, often being proceeded by potentially
malignant disorders (PMD). Early detection can reduce the malignant transformation of PMD and can improve the survival rate
for oral cancer. The current standard of scalpel biopsy with histology is painful for patients and involves a delay whilst histology is
completed; other tests are available that are unobtrusive and provide immediate results.
Objectives
Primary objective: To estimate the diagnostic accuracy of index tests for the detection of oral cancer and PMD of the lip and oral cavity,
in people presenting with clinically evident lesions.
Secondary objective: To estimate the relative accuracy of the different index tests.
Search methods
The electronic databases were searched on 30 April 2013. We searched MEDLINE (OVID) (1946 to April 2013) and four other
electronic databases (the Cochrane Diagnostic Test Accuracy Studies Register, the Cochrane Oral Health Group’s Trials Register,
EMBASE (OVID) and MEDION (Ovid)). There were no restrictions on language in the searches of the electronic databases. We
conducted citation searches and screened reference lists of included studies for additional references.
Selection criteria
We selected studies that reported the diagnostic test accuracy of the following index tests when used as an adjunct to conventional
oral examination in detecting PMD or oral squamous cell carcinoma of the lip or oral cavity: vital staining, oral cytology, light-based
detection and oral spectroscopy, blood or saliva analysis (which test for the presence of biomarkers in blood or saliva).
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Data collection and analysis
Two review authors independently screened titles and abstracts for relevance. Eligibility, data extraction and quality assessment were
carried out by at least two authors, independently and in duplicate. Studies were assessed for methodological quality using QUADAS-
2. Meta-analysis was used to combine the results of studies for each index test using the bivariate approach to estimate the expected
values of sensitivity and specificity.
Main results
We included 41 studies, recruiting 4002 participants, in this review. These studies evaluated the diagnostic accuracy of conventional
oral examination with: vital staining (14 studies), oral cytology (13 studies), light-based detection or oral spectroscopy (13 studies).
Six studies assessed two combined index tests. There were no eligible diagnostic accuracy studies evaluating blood or salivary sample
analysis.
The summary estimates for vital staining obtained from themeta-analysis were sensitivity of 0.84 (95%CI 0.74 to 0.90) with specificity
of 0.70 (0.59 to 0.79), with 14 studies were included in themeta-analysis. For cytology, sensitivity was 0.91 (0.81 to 0.96) and specificity
was 0.91 (0.81 to 0.95) with 12 studies included in the meta-analysis. For light-based detection, sensitivity was 0.91 (0.77 to 0.97)
and specificity was 0.58 (0.22 to 0.87) with 11 studies included in the meta-analysis. The relative test accuracy was assessed by adding
covariates to the bivariate analysis, no difference in model fit was observed.
Authors’ conclusions
The overall quality of the included studies was poor. None of the adjunctive tests can be recommended as a replacement for the currently
used standard of a scalpel biopsy and histological assessment. Given the relatively high values of the summary estimates of sensitivity
and specificity for cytology, this would appear to offer the most potential. Combined adjunctive tests involving cytology warrant further
investigation.
P L A I N L A N G U A G E S U M M A R Y
What are the most accurate tests for finding cancer of the mouth or lips (oral cancer) and conditions that may lead to oral
cancer?
Review question
The current method of diagnosing cancer of the mouth or lips involves the surgical removal of a piece of affected tissue that is sent to
a laboratory for histological examination using a microscope (scalpel biopsy). This is painful for patients and involves a delay. The aim
of this review was to find out the accuracy of three alternative diagnostic tests that are less invasive and provide more timely results.
Background
Oral cancer (OSCC - oral squamous cell carcinoma) often occurs after a condition called PMD (potentially malignant disorder), which
can sometimes progress to cancer. If conditions such as oral cancer or PMD are identified early enough, outcomes for patients can be
improved.
Study characteristics
The search on which the evidence is based was carried out on 30 April 2013. Forty-one studies involving 4002 participants, published
between 1980 and 2012, were included. Each participant underwent one of three diagnostic tests for oral cancer and PMD as well as
the standard method of diagnosis by surgical biopsy. By comparing results, the researchers were able to evaluate the accuracy of each
test as compared to surgical biopsy.
Three tests (index tests) were evaluated.
1. Vital stain - a liquid that can be used as a mouthrinse or applied straight on to a suspected area of the mouth. It is thought that any
area that is coloured blue after rinsing with water has a high chance of being oral cancer or PMD.
2. Oral cytology - instead of using a scalpel to cut away a piece of the suspected area, a brush is used to remove cells that are sent to a
laboratory for examination under a microscope.
3. Light-based detection - a special light shone in the mouth that is believed to make cancerous areas appear different to healthy areas.
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There were no eligible studies that looked at the accuracy of tests of blood or saliva.
Key Results
The proportion of people with OSCC or PMD identified through surgical biopsy varied in the included studies. We used the middle
value for the included studies to illustrate the implications of the different tests. A false negative result means that people that truly have
oral cancer or PMD will be diagnosed as free from the condition, possibly to be correctly diagnosed at a later date when the condition
will be more difficult to treat successfully. A false positive result would mean that people who did not truly have PMD or oral cancer
would be diagnosed as having it and therefore unnecessarily undergo invasive treatment.
If vital staining was used to identify OSCC or PMD in a sample of 1000 people (of whom 500 truly have OSCC or PMD), then
the condition would go undetected in 80 people (false negative result) and 150 people without the condition would be told they have
the condition (false positive result). If cytology was used, the condition would go undetected in 45 people and 45 people without the
condition would be told they have the condition. If a light-based detection method was used, the condition would go undetected in
45 people and 210 people without the condition would told they have the condition.
Therefore, in terms of correctly classifying people, cytology was the most accurate of the three tests.
Quality of the evidence
There were shortcomings in many of the studies that put them at high risk of bias and so the key results should be interpreted with
caution. The main concern was the ways in which people were selected to take part in the studies. When patients at particularly high or
low risk of oral cancer are selected to participate then this can influence the results of the study. Additionally, there were studies where
the results from the standard method of diagnosis (’index test’) were not reported and the reasons for this were not explained.
Conclusion
None of the tests evaluated in this review that were additional to a visual examination can be recommended as a replacement for the
currently used standard of a scalpel biopsy and histological assessment.
B A C K G R O U N D
Target condition being diagnosed
The target conditions of interest are oral squamous cell carcinoma
(OSCC) and potentiallymalignant disorders (PMD) of the lip and
oral cavity. OSCC is the most common form of oral cavity cancer
(Scully 2000a) and many are preceded by PMD. PMD represent a
heterogeneous group of conditions including erythroplakia, non-
homogeneous leukoplakia, erosive lichen planus, oral submucous
fibrosis and actinic keratosis (Warnakulasuriya 2007).
The natural history of OSCC is not fully understood; not all
PMD undergo malignant transformation and some affected sites
can revert back to health (Napier 2008; Scully 2009). Equally,
someOSCCcan develop from lesions in which epithelial dysplasia
was not previously diagnosed. Erythroplakia and erythro-leuko-
plakia have amongst the highest malignant transformation rates,
followed by oral submucous fibrosis (Scully 2009). Oral leuko-
plakia is the most common PMD, but has a varied malignant
transformation rate (Reibul 2003; Napier 2008; Mehanna 2009;
Scully 2009). Petti 2003 calculated a global malignant transfor-
mation rate (MTR) of oral leukoplakia of 1.36% per year (95%
confidence interval 0.69 to 2.03%), but when this is applied to the
prevalence of the condition, it far exceeds the numbers of actual
cases of malignancy that present. However, the MTR in hospital-
based studies is consistently higher than the MTR in community-
based studies.
The early detection and excision of PMD can prevent malig-
nant transformation (Warnakulasuriya 2007; van der Waal 2009;
Brocklehurst 2013). Leukoplakias can be treated by a number of
different methods although there remains some debate in the lit-
erature as to their effectiveness and there is limited empirical ev-
idence (Holmstrup 2006; Lodi 2008). Systematic reviews have
identified no experimental evidence for surgical interventions (in-
cluding laser therapy and cryotherapy) and little experimental ev-
idence for non-surgical interventions. In addition, where clini-
cal resolution was observed, relapses were common (Lodi 2008;
Mehanna 2009).
In the United Kingdom, patients presenting with oral lesions per-
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sisting for more than two to three weeks are generally referred to
Oral Medicine Units or Oral and Maxillofacial Surgery Units for
further investigation (Scully 2000a; Scully 2000b; Scully 2000c).
Technologies to treat and manage oral cancer have progressed sub-
stantially (Glenny 2010; Furness 2011; Bessell 2011).Despite this,
mortality rates have remained high (approximately 50%) and have
not improved over the last 30 years (Parkin 2001;Warnakulasuriya
2009). If the lesion has progressed to frank malignancy, the tra-
ditional treatment is surgery and radiotherapy, but the associated
morbidity is high. This is in marked contrast to the improved
survival rates in many other cancers, such as those of the breast
and the colon (Cancer Research UK). Reasons for this include late
presentation by the patient (early cancers are often asymptomatic,
such that the patient is unaware of it) and delayed diagnosis (a
combination of patient factors such as infrequent dental atten-
dance and dental professional factors, such as failure to screen the
entire mouth, failure to raise their index of suspicion regarding
any lesion they may see or delays in onward referral). Yet oral can-
cer can be cured if caught early enough (Stell 1982). It has been
estimated that in the UK, 80% of the population will visit a den-
tist at least once in the previous five years (Tilley 2005). Hence
the dental team must screen every patient they see, particularly
irregular attenders.
Index test(s)
A number of index tests have been proposed as adjuncts to a con-
ventional oral examination (COE) to improve diagnostic test ac-
curacy (Lingen 2008; Patton 2008; Fedele 2009; Leston 2010;
Rethman 2010).
• Vital staining (toluidine blue, tolonium chloride)
• Oral cytology (e.g. OralCDx brush biopsy)
• Light-based detection (e.g. ViziLite, Microlux/DL,
VELscope, Orascoptic DK, Identafi 3000) and oral spectroscopy
• Blood and saliva analysis
We evaluated all four categories of index tests in this review (re-
stricting vital staining index tests to those applied to a visible le-
sion). All have the potential to be used as diagnostic or case-finding
adjuncts to the COE by clinicians or other health professionals
(Table 1), to aid in the diagnosis of OSCC and PMD.
Clinical pathway
There is no internationally recognised or standardised clinical
pathway for individuals presenting with PMD. Commonly, indi-
viduals receive a COE from frontline clinicians as part of a routine
dental appointment. The COE involves a standard visual and tac-
tile examination of the oral mucosa under normal (incandescent)
light. Alternatively, patientsmay occasionally present to a frontline
clinician with symptoms. Upon discovering a lesion, the clinician
makes a subjective judgement based upon the clinical presenta-
tion. If PMD or malignancy is suspected, the frontline clinician
refers on to an oral specialist for a definitive diagnosis and scalpel
biopsy, as appropriate.
Supplementing the COE with an index test could aid in the iden-
tification of clinically evident lesions. Tests could have a triage role
in assisting the general dentist or oral specialist to more accurately
assess oral lesions of uncertain significance. It could also help to
reduce the unnecessary referral of benign conditions. For instance,
traumatic keratoses are common benign white lesions and refer-
ring every patient would be excessive and incur increased financial
cost and anxiety for the referred patient. A non-invasive index test
or combination of tests adjunctive to the COE could provide a
frontline clinician with sufficient information to reduce the num-
ber of unnecessary referrals.
The index tests have the potential to improve patient diagnosis at
a secondary care level. Following referral to a specialist clinic, a
scalpel biopsy is commonly undertaken on areas representing the
worst of the disease. This becomes complicated when the lesion or
lesions under investigation are large or heterogeneous in nature.
Sample site selection may be facilitated by the use of diagnostic
adjuncts. The tests could also be used to help monitor a patient
who has had a history of oral cancer or PMD. This population
has often been exposed to surgical procedures, radiotherapy and
repeated biopsies. Monitoring these patients for new disease can
become complicated due to field change, where previously healthy
mucosa undergoes malignant transformation. Determining the
most appropriate site for a biopsy is challenging and the diagnostic
adjuncts could be of value.
Alternative test(s)
TheCOEhas been investigated as a test for early detectionof PMD
(Walsh 2013) and traditionally would be the first test applied. The
only alternative tests are the adjunctive tests (which form the index
tests of this review) and the incisional biopsy (which acts as the
reference standard).
Rationale
Oral cancer is a significant global health problem with increas-
ing incidence and mortality rates (Warnakulasuriya 2009; Ferlay
2010). Cancer of the lip or oral cavity is a relatively common can-
cer worldwide, with an estimated 263,000 new cases and 127,000
deaths in 2008, and an increasing incidence of disease in recent
years (Ferlay 2010). There is wide geographic variation in disease
incidence and mortality, with almost double the incidence in de-
veloping countries compared to developed countries, and a three-
fold increase in mortality. Tobacco use, alcohol consumption, be-
tel quid chewing and low socioeconomic status are the most im-
portant risk factors for oral cancer (Macfarlane 1995; Faggiano
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1997; La Vecchia 1997; Conway 2008). Men have a higher inci-
dence of oral cancer than women, but the gender difference has
narrowed in recent decades from a ratio of 5 males to 1 female
diagnosed with oral cancers in the 1960s to less than 2 to 1 in
2008 (Ferlay 2010). Although traditionally the risk of oral cancer
increases with age, the incidence in recent years among younger
adults has increased in the European Union and the United States
(Warnakulasuriya 2009).
Oral cancer mortality can be reduced by: (i) primary prevention,
(ii) secondary prevention (screening and early detection) and (iii)
improved treatment (Scully 2000a). Accurate case detection and
early treatment of oral cancers can substantially improve an indi-
vidual’s morbidity, mortality and quality of life (Stell 1982; Scully
2000a). However, no national population-based screening pro-
grammes for oral cancer have been implemented in developed
countries, although opportunistic screening has been advocated
(Brocklehurst 2013). A province-wide programme is being eval-
uated in British Columbia, Canada but the evaluation is ongo-
ing and no final results have been reported to date (Rosin 2006).
Brocklehurst et al’s Cochrane systematic review identified one
randomised controlled trial (RCT) from India. They concluded
that the evidence is insufficient to recommend population-based
screening but opportunistic screening of high-risk groups may po-
tentially improve outcomes (Brocklehurst 2013).
Oral cancer is often diagnosed at a late stage, when the prognosis
is poor and the risks of significant morbidity and mortality are
substantially higher (Rusthoven 2010). Technologies to treat and
manage oral cancer have progressed substantially (Glenny 2010;
Furness 2011), but the five-year survival following diagnosis has
remained constant at around 50% for the past 30 years (Parkin
2001; Warnakulasuriya 2009; Cancer Research UK).
In this review, we aimed to identify diagnostic tests for OSCC and
PMD and to evaluate the diagnostic accuracy of these tests (Table
1) when used as adjuncts to a COE by clinicians in a secondary
care facility.
This diagnostic test accuracy review complements a number of
intervention reviews undertaken by the Cochrane Oral Health
Groupon the treatment of oral and oropharyngeal cancers (Glenny
2010; Furness 2011; Bessell 2011), screening programmes for the
early detection and prevention of oral cancer (Brocklehurst 2013)
and clinical assessment to screen for the detection of oral cavity
cancer and potentially malignant disorders in apparently healthy
adults (Walsh 2013).
O B J E C T I V E S
To estimate the diagnostic accuracy of index tests for the detection
of oral cancer and potentially malignant disorders of the lip and
oral cavity, in patients presenting with clinically evident lesions.
Secondary objectives
To estimate the relative accuracy of the different index tests.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies evaluating index test(s) that reported on the diagnostic
accuracy for individuals presenting with clinically evident lesions.
The index tests assessed in this review are provided in Table 1.
Eligible study designs included cross-sectional diagnostic test ac-
curacy studies (or consecutive series) and randomised studies of
diagnostic test accuracy. We excluded studies that reported in ab-
stract form alone, case-control studies, uncontrolled reports and
randomised controlled trials (RCTs) of the effectiveness of screen-
ing programmes (intervention studies).
We had intended to exclude studies that analysed at the lesion
level rather than at the individual level, unless the authors could
provide patient-level data. In a change from the original protocol,
we included studies reporting at the lesion level, and identified
these studies in any analyses.
Participants
Adults (aged 16 years or over) presenting with clinically evident
oral lesions.
Index tests
Index tests used alone, or in combination, as an adjunct to the
COE (Table 1). Where multiple index tests were used together,
we classed as positive a positive test result from the COE or the
index test or both.
Target conditions
Following the consensus views of the expert working group of
the WHO collaborating centre for oral cancer and pre-cancer (
Warnakulasuriya 2007), the following target conditions of the lip
or oral cavity were considered for inclusion in this review.
Carcinoma
• Oral squamous cell carcinoma (OSCC)
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• Hereditary disorders such as dyskeratosis congenita or
epidermolysis bullosa
This review classified any level of dysplasia (mild, moderate or
severe) as the target condition.
Reference standards
Scalpel, punch or fine needle aspiration biopsy with histological
diagnosis. Studies not specifying any reference standard were in-
eligible for inclusion in this review.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases.
• Cochrane Oral Health Group’s Trials Register (to 30 April
2013) (see Appendix 1)
• Cochrane Register of Diagnostic Test Accuracy Studies (to
30 April 2013) (see Appendix 2)
• MEDLINE via OVID (1946 to 30 April 2013) (see
Appendix 3)
• EMBASE via OVID (1980 to 30 April 2013) (see
Appendix 4)
• MEDION (2003 to 30 April 2013) (see Appendix 5)
TheMEDLINE search strategy outlined in Appendix 3. was mod-
ified for the listed databases and was based on the companion
Cochrane diagnostic test accuracy review (Walsh 2013) under-
taken by the same team. The search was not limited by language
or publication status. Non-English studies were translated.
Searching other resources
We searched the reference lists of key studies and contacted authors
of studies to ask if they were aware of any unpublished or ongoing
studies.
Data collection and analysis
Selection of studies
Two of the review authors independently assessed titles and ab-
stracts of all identified studies from the electronic searches. Full
reports were obtained for studies that appeared to meet the inclu-
sion criteria, or where a clear decision could not be made from
the title and abstract alone. Where disagreements occurred, we re-
solved these by discussion or by consulting a third review author.
Data extraction and management
Two review authors independently extracted data using a piloted
data collection form and, where necessary, study authors were con-
tacted to obtain relevant data missing from the full paper.
The following data were recorded from each study.
• Sample characteristics (age, sex, socioeconomic status, risk
factors where stated (e.g. human papillomavirus status positive/
negative, prevalence of tobacco use and alcohol consumption),
number of patients/lesions, lesion site)
• Setting (country, disease prevalence, type of facility)
• The type of index test(s) used (category, name, positivity
threshold)
• Study information (design, reference standard, case
definition, training and calibration of personnel)
• Study results (true positive, true negative, false positive,
false negative, any equivocal results, withdrawal)
We had planned to extract data according to subgroup (tobacco
and alcohol consumption) but these data were rarely reported in
the studies.
Assessment of methodological quality
Two review authors independently assessed the quality of the in-
cluded studies. Where disagreements occurred, these were either
resolved by discussion or by consulting a third review author. We
modified QUADAS-2 (Whiting 2011), piloted it on five studies
and then used it to assess the methodological quality of the diag-
nostic studies over four key domains: patient selection, index test,
reference standard, and flow and timing of participants through
the study (Table 2).
Two core signalling questions were removed as theywere addressed
by the eligibility criteria: ’Was a case-control design avoided?’ and
’Did all patients receive a reference standard?’. Three additional
signalling items were added relating to commercial funding, train-
ing and calibration, and multiple index tests.
A ’Risk of bias’ judgement (’high’, ’low’ or ’unclear’) was made for
each domain. If the answers to all signalling questions within a
domain were judged as ’yes’ (indicating low risk of bias for each
question) then the domain was judged to be at low risk of bias. If
any signalling question was judged as ’no’, indicating a high risk
of bias, the domain was scored as a high risk of bias. This was
followedby a judgement about concerns regarding applicability for
the patient selection, index test and reference standard domains.
Results of the assessment of methodological quality were also pre-
sented graphically.
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Statistical analysis and data synthesis
We entered data for the true positive, true negative, false positive
and false negative values for each test in each study into Review
Manager Rev Man 2014). The unit of analysis was the lesion.
Where study results were only recorded at the lesion level, these
studies were included as reported but identified in the forest plots.
The average number of lesions per individual analysed is provided
in the Characteristics of included studies section. For each index
test, estimates of the diagnostic accuracy are expressed as sensi-
tivity and specificity along with 95% confidence intervals. This
information is displayed as coupled forest plots, and plotted in
receiver operating characteristic (ROC) space.
Meta-analysis was used to combine the results of studies for each
index test using the bivariate approach to estimate the expected
values of sensitivity and specificity (Reitsma 2005).
Indirect pairwise analyses were also structured as follows:
• vital staining versus brush cytology;
• light detection versus brush cytology;
• vital staining versus light detection.
We included all studies in each pairwise comparison. We also pre-
sented results of studies that directly compared different index tests
(i.e. paired data from all individuals or individuals randomised
to different index tests) in additional forest plots. SAS and Stata
(version 13) were used for all statistical analyses. In light of the
number of studies available, we also undertook comparative anal-
yses where we relaxed the assumption of equal variances.
Investigations of heterogeneity
We carried outmeta-regression analyses to explore possible sources
of heterogeneity. Covariates in these analyses included:
• characteristics of the study sample: prevalence of the disease
in the study;
• methods used by index test: rinsing or targeted staining
with the vital staining products or classification of fluorescence
device for light-based studies.
We had intended to investigate the severity of the target condition
as another potential source of heterogeneity. As the majority of
studies included ’any dysplasia’ as the target condition, there was
insufficient variation in the included studies to do this.
The log likelihoodofmodels including the covariatewas compared
to those models without the covariate. Formal model comparisons
were undertaken using the likelihood ratio statistic to statistically
compare the effects of adding or removing one or more covariate,
with the assumption of equal variances.
Sensitivity analyses
We intended to carry out a sensitivity analyses that restricted the
analysis to studies where the reference standard was scalpel biopsy
followed by histopathology. We were unable to do this as the ref-
erence standard in all the included studies was scalpel biopsy.
Assessment of reporting bias
We did not undertake tests for reporting bias as these can be mis-
leading when applied to systematic reviews of diagnostic test ac-
curacy (Tang 2000; Leeflang 2008).
R E S U L T S
Results of the search
The search identified a total of 10,593 records, after duplicates
were removed. We excluded 10,354 in accordance with the eli-
gibility criteria and the remaining 239 studies were assessed for
eligibility. Forty-one of these studies were eligible for inclusion
(Figure 1). These studies evaluated data from a total of 4002 pa-
tients and 4337 lesions, with a mean number of patients per study
of 97.61. There was a broad geographical spread: 18 of the studies
were of European origin, 12 from India, five from the US, three
from Australia and one from Brazil; the remainder originated in
Asia. The studies were conducted between 1980 and 2012.
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Figure 1. Study flow diagram
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Of the four categories of index tests proposed for evaluation, we
identified studies reporting the diagnostic test accuracy of vital
staining, oral cytology and light-based detection methods. No el-
igible studies assessed the diagnostic test accuracy of blood and
saliva analysis in the detection of OSCC or PMD. All included
studies were carried out in a secondary care (hospital) setting.
Thirty studies evaluated a single adjunct test on a single sam-
ple. Of the remaining 11 studies, four assessed multiple tests on
the same sample (Mehrotra 2010; Awan 2011; Ujaoney 2012;
Rahman 2012); one assessed a single test on different samples
(Cheng 2003a; Cheng 2003b) and six evaluated index tests used in
combination (Gupta 2007; Epstein 2008;Mehrotra 2010; Guneri
2011; Mojsa 2012; Ujaoney 2012).
For the purposes of evaluation:
• Fourteen studies evaluated vital staining: 12 used toluidine
blue (or methylene blue), one used toluidine blue and/or Lugol’s
Iodine (Nagaraju 2010) and one used Rose Bengal (Du 2007).
Nine of these studies used a mouth rinse technique whilst four
used a direct staining approach. One study (Cheng 2003a;
Cheng 2003b) made a comparison between rinse and stain and
has therefore been reported separately to allow for analysis of this
covariate.
• Thirteen studies evaluated oral cytology, 12 of which used a
brush to harvest cells: five assessed the Oral CDx system
(Sciubba 1999; Svirsky 2002; Scheifele 2004; Delavarian 2010;
Seijas-Naya 2012), three assessed the Cytobrush (Navone 2004;
Koch 2011a; Rahman 2012) and the remainder used other
brush-based methods (Mehrotra 2008; Remmerbach 2009;
Mehrotra 2011; Ng 2012). One study (Navone 2008) used a
curette to harvest cells.
• Thirteen studies evaluated light-based technologies: four
assessed the VELScope device (Mehrotra 2010; Awan 2011;
Scheer 2011; Farah 2012), three assessed the Vizilite device
(Farah 2007; Awan 2011; Ujaoney 2012); the remaining six
assessed other light-based technologies.
• Six studies evaluated index tests used in combination: four
assessed vital staining with light-based detection (Epstein 2008;
Mehrotra 2010; Mojsa 2012; Ujaoney 2012) and two assessed
the use of vital staining with cytology (Gupta 2007; Guneri
2011).
All studies used a reference test of scalpel biopsy and histological
examination; no punch of fine needle biopsies were observed. All
studies were set within a secondary care environment.
The main reasons for exclusion were inappropriate patient selec-
tion or the reference standard not being applied to all patients. Fur-
ther details are provided in the Characteristics of excluded studies
table.
Methodological quality of included studies
Figure 2 summarises the results of the quality assessment of the
included studies. No single study could be classified as being at
low risk of bias across all domains. Individual assessment for each
study is provided in Figure 3.
Figure 2. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies
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Figure 3. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
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Patient selection was considered to be at low risk of bias in nine out
of 41 of studies (22%). Twenty of the 41 studies (49%) failed to
describe the patient selection criteria in sufficient detail and were
therefore assessed as being at unclear risk of bias. Eleven studies
selected patients that were either at high or low risk and therefore
inappropriately excluded people (Sciubba 1999; Svirsky 2002;
Scheifele 2004; Du 2007; Epstein 2008; Mehrotra 2010; Scheer
2011; Upadhyay 2011; Seijas-Naya 2012; Farah 2012; Ujaoney
2012).Onofre 2001 failed to use consecutive or random sampling.
The index test was considered to be at unclear risk of bias in
28 out of 41 studies (68%). The most common reason was a
lack of detail about training or calibration of the clinicians. Only
six of the included studies had a training or calibration compo-
nent (Sciubba 1999; Onofre 2001; Mehrotra 2011; Awan 2011;
Cancela-Rodriguez 2011; Farah 2012). In addition, a number of
conflicts of interest were found where authors had links to compa-
nies supplying or developing the diagnostic aids being investigated
(Silverman 1984; Sciubba 1999; Svirsky 2002; Scheifele 2004;
Epstein 2008; Ng 2012). The positivity threshold was assessed as
being at a high risk of bias in one study (Navone 2008). There
was uncertainty in how the results of the cytology were graded in
two studies, when there was an inadequate harvest of basal cells
(Sciubba 1999; Scheifele 2004), which made interpretation and
data extraction difficult. Finally, it was not possible to determine
the order of the index tests in one study where multiple index tests
were used (Mehrotra 2010).
All of the included studies used an appropriate reference standard;
a scalpel biopsy followed by a histological examination by an ex-
perienced oral pathologist. However, many did not provide suf-
ficient detail about the scalpel biopsy or the thresholds used in
the histological examination. Three studies failed to ensure that
the reference test was conducted independent of the results of the
index test: Onizawa 1999, Navone 2008 and Seijas-Naya 2012, in
which the same pathologist undertook the brush biopsy and the
histological examination.
We deemed 23 of the studies to be at low risk of bias regarding
the flow and timing of the study. Most studies reported a minimal
time delay between the index test and the reference standard or
this could be inferred from the description of the methods. We
classified 11 studies as unclear as they failed to report the tim-
ing difference. We found seven studies to be at high risk, five of
these excluded participants from the analysis despite them receiv-
ing both index and reference tests (Warnakulasuriya 1996;Navone
2004; Scheifele 2004; Sharwani 2006b; Awan 2012), while one
reported a delay of three weeks between index and reference tests
(Seijas-Naya 2012) and one allowed participants to receive the in-
dex test without a reference test (Awan 2011).
We assessed 20 studies as having low concern for applicability:
patient selection, the index test and the reference standard used
were generalisable across the population attending secondary care.
We recorded an unclear level of concern when a population had
been selected to bemade up of high or low risk patients only. Index
and reference tests were classified as unclear when the description




From the 14 studies evaluating this test (Cheng 2003a evaluated
two separate samples resulting in 15 data points for sensitivity and
specificity), we included 1248 individuals and 1338 lesions in the
analysis. The definition of the target condition varied between the
studies: all classified OSCC as positive; 12 of the studies reported
any dysplasia as positive or we were able to re-classify according to
this threshold. Ujaoney 2012 used a positivity threshold of ’high
risk lesion’ and we were unable to re-analyse. Rahman 2012 was
also unclear but an assumption was made that any blue staining
was classified as positive. Three studies reported data at the lesion
level (Mashberg 1980, average number of lesions per individual
1.32; Ujaoney 2012, 1.80; Warnakulasuriya 1996, 1.42).
The summary estimates obtained from the meta-analysis were:
sensitivity of 0.84 (0.74 to 0.90) with specificity of 0.70 (0.59 to
0.79) (Figure 4; Figure 5). If vital staining was used to identify
PMD or OSCC in a sample of 1000 people, of whom 500 had
the target condition (a median prevalence of positive lesions from
the histological diagnosis of vital staining studies of 50%), then
the target condition would go undetected in 80 individuals (false
negative result) and 150 individuals without disease would be
misclassified with a positive result (false positive result).
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Figure 4. Forest plot of Vital staining
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Figure 5. Summary ROC Plot of Vital staining
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The coupled forest plot is presented along with the estimates of
sensitivity and specificity for each study and plotted in ROC space.
There was considerable variation in the estimates of both sensitiv-
ity and specificity. This is reflected in the coverage of the 95% con-
fidence region (uncertainty in the overall average values of sensitiv-
ity and specificity due to sampling variation) and the 50% predic-
tion region (a measure of between-study variability corresponding
to the equivalent of an interquartile range in this instance).
We undertook meta-regression analysis to explore potential
sources of heterogeneity as specified in the protocol. The results of
the covariate analysis indicated that neither sensitivity nor speci-
ficity were associated with prevalence of disease (P = 0.14) or mode
of administration (five studies used a rinse compared to 10 studies
using a stain) (P = 0.95).
Oral cytology
In the 13 studies that evaluated oral cytology, 1554 participants
and 1622 lesions were examined. The definition of the target con-
dition was consistently OSCC, carcinoma in situ (CIS) and all
forms of dysplasia; except for Rahman 2012, which created an
“atypia” group and there was no clarity on how these were treated.
Three studies reported data at the lesion level (Delavarian 2010,
average number of lesions per individual 1.04; Koch 2011a, 1.35;
Scheifele 2004, 1.20).
We excluded one study that reported the results of multiple di-
rect cytology tests (Remmerbach 2009) from the meta-analysis
due to the potential of triple counting (as per guidance in the
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accu-
racy, Macaskill 2010).The summary estimates obtained from the
meta-analysis of 12 studies of sensitivity were 0.91 (0.81 to 0.96)
and a specificity of 0.91 (0.81 to 0.95) (Figure 6; Figure 7). If
cytology was used to identify OSCC and PMD in a sample of
1000 people, with the cytology studies reporting a median preva-
lence of the target condition of 43%, then the disease would go
undetected in 39 individuals and 51 individuals without disease
would be misclassified with a positive result.
Figure 6. Forest plot of Cytology
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Figure 7. Summary ROC Plot of Cytology
The coupled forest plot is presented along with the estimates of
sensitivity and specificity for each study and plotted in ROC space.
There was some variation in the estimates of sensitivity; this was
less evident for estimates of specificity. This is reflected in the
coverage of the 95% confidence region and the 50% prediction
region. There are two studies for which the results are atypical of
the included studies. One study reported low values of specificity
but high values of sensitivity (Svirsky 2002); one study reported
low values of sensitivity but high values of specificity (Ng 2012).
We undertook meta-regression analysis to explore the prevalence
of dysplasia and OSCC as a potential source of heterogeneity
as specified in the protocol. The results of the covariate analysis
showed that neither sensitivity nor specificity were associated with
prevalence of disease (P = 0.45). We had planned to investigate
different methods of biopsy, but there were too few studies for
each method for the results of the analysis to be robust: OralCDX
(five studies), CytoBrush (two studies), curette (one study) and
other (six studies).
Light-based detection and/or oral spectroscopy
Thirteen studies evaluated data from 1253 patients and 1397 le-
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sions. The target conditions wereOSCC and all forms of dysplasia
in 10 of the studies, and we were able to re-classify one other study
according to this threshold (Leunig 2000). One study reported a
definition of the target condition as “high-risk” (Ujaoney 2012)
and another reported OSCC alone (Scheer 2011).The studies by
Scheer 2011 and Ujaoney 2012 also excluded patients with ad-
vanced OSCC and therefore failed to report data from the full
patient spectrum. Three studies reported data at the lesion level
(Farah 2012, average number of lesions per individual 1.05; Leunig
2000, 2.76; Ujaoney 2012, 1.80).
We excluded one study from the meta-analysis due to incomplete
data reporting (Kulapaditharon 1998). In this study the diagnos-
tic test accuracy of white light endoscopy was evaluated in 11 pa-
tients, but true negative results were not fully reported and there-
fore no specificity estimates could be calculated. We also excluded
one study that reported the results of multiple direct light-based
tests (Awan 2011) from the meta-analysis due to the potential of
double counting (as per guidance inMacaskill 2010). The 126 pa-
tients included in this study would make up a high proportion of
participants for this index test and therefore have an impact on the
pooled estimate. The sensitivity and specificity of autofluorescence
(VELScope) for the detection of a dysplastic lesion were 0.84 and
0.15, respectively; the sensitivity and specificity of chemilumines-
cence (Vizilite) for the detection of a dysplastic lesion were 0.77
and 0.28, respectively (Awan 2011).
The meta-analysis yielded estimates of sensitivity of 0.91 (0.77 to
0.97) and specificity of 0.58 (0.22 to 0.87) (Figure 8; Figure 9).
If a light-based detection method was used to identify OSCC and
PMD in a sample of 1000 people, with the light-based studies
reporting a median prevalence of the target condition of 21%,
then the disease would go undetected in 19 individuals and 332
individuals without disease would be mis-classified with a positive
result. The coupled forest plot is presented alongwith the estimates
of sensitivity and specificity and plotted in ROC space. There
are two studies for which the results are atypical of the included
studies. Both of these studies reported very low values of specificity
with very high values of sensitivity (Farah 2007; Ujaoney 2012).
Figure 8. Forest plot of Light-based
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Figure 9. Summary ROC Plot of Light-based
Vital staining plus adjunct
Six studies with 402 individuals and 478 lesions used a vital stain-
ing with an adjunctive diagnostic test: four assessed vital staining
with light-based detection (Epstein 2008; Mehrotra 2010; Mojsa
2012; Ujaoney 2012) (see Data table 4) and two assessed the use
of vital staining with cytology (Gupta 2007; Guneri 2011) (see
Data table 5). Due to the small number of studies, we did not
carry out a meta-analysis of this data.
Relative performance of different tests
We added a covariate of test type to the bivariate analysis to as-
certain the relative diagnostic test accuracy of the different tests.
In accordance with the protocol, we carried out three pairwise
comparisons. No difference in model fit was observed where equal
variances were assumed except for the comparison highlighted be-
low.
• Vital staining versus cytology
• Vital staining versus light-based detection (not assuming
equal variances)
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• Cytology versus light-based detection
The results of the model comparisons are presented in Table 3.
Vital staining versus cytology
This comparison was based on data from 14 studies of vital stain-
ing (from 15 different samples) and 12 studies of cytology. The
coupled forest plot is presented along with the estimates of sensi-
tivity and specificity and plotted in ROC space. The analysis con-
tained paired data for one study (Rahman 2012). Initial analysis
indicated that the expected summary measures of sensitivity and/
or specificity differed between the vital staining and cytology tests
(P = 0.004). Further exploration indicated that there was no statis-
tical evidence that sensitivity differed between vital staining com-
pared to cytology (P = 0.23), but that there was strong statistical
evidence that specificity differed between vital staining compared
to cytology (P = 0.003). (Vital staining sensitivity 0.84 (0.74 to
0.90) and specificity 0.70 (0.59 to 0.79); cytology sensitivity 0.91
(0.81 to 0.96) and specificity of 0.91 (0.81 to 0.95)).
There was no statistical evidence (P = 0.55) to suggest that the as-
sumption of equal variances was violated. Assuming the variances
to be the same the values for sensitivity and specificity of stain
and cytology the following values resulted: Vital staining sensitiv-
ity 0.84 (0.73 to 0.91) and specificity 0.69 (0.55 to 0.80); cytol-
ogy sensitivity 0.91 (0.82 to 0.96) and specificity of 0.90 (0.82 to
0.95).
Vital staining versus light-based detection
This comparison was based on data from 14 studies of vital stain-
ing (from 15 different samples) and 11 studies of light-based de-
tection. The coupled forest plot is presented along with the es-
timates of sensitivity and specificity and plotted in ROC space.
The analysis contained paired data for one study (Ujaoney 2012).
Results of the analyses indicated that the expected summary mea-
sures of sensitivity and/or specificity did not differ between the
vital staining and light-based detection (P = 0.49). (Vital staining
sensitivity 0.84 (0.74 to 0.90) and specificity 0.70 (0.59 to 0.79);
light-based detection sensitivity of 0.91 (0.77 to 0.97), specificity
0.58 (0.22 to 0.87)). For this comparison there was statistical evi-
dence (P = 0.01) to suggest that the assumption of equal variances
may not be reasonable (estimates not assuming equal variances are
provided).
Cytology versus light-based detection
This comparison was based on data from 12 studies of cytology
and 11 studies of light-based detection. The coupled forest plot
is presented along with the estimates of sensitivity and specificity
and plotted in ROC space. Initial analysis indicated that there
was weak evidence that expected summary measures of sensitivity
and/or specificity differed between the cytology and light-based
detection (P = 0.06). Further exploration indicated that there was
no statistical evidence that sensitivity differed between cytology
and light-based detection (P = 0.99), but that there was strong
statistical evidence that specificity differed between vital staining
compared to cytology (P = 0.02). (Cytology sensitivity 0.91 (0.81
to 0.96) and specificity of 0.91 (0.81 to 0.95), light-based detec-
tion sensitivity 0.91 (0.77 to 0.0.97) and specificity 0.58 (0.22 to
0.87)).
Comparison of the models with covariates assuming and not as-
suming equal variances was not statistically significant (P = 0.21).
Assuming the variances to be the same the following values re-
sulted: cytology sensitivity 0.91 (0.81 to 0.96) and specificity of
0.91 (0.77 to 0.97), light-based detection sensitivity 0.91 (0.78 to
0.0.97) and specificity 0.59 (0.31 to 0.82).
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Summary of findings
What is the most accurate health technology for diagnosing oral cancer and potentially malignant disorders?
Patient population Patients referred to a secondary care facility for further investigation of a clinically evident lesion
Index test Conventional oral examination and adjunctive test (Vital Stain, Oral Cytology, Light-based)
Reference test Scalpel biopsy and histological assessment by experienced oral pathologist
Target condition Oral cavity cancer or potentially malignant disorder











Vital Staining 0.84 (0.74 to 0.90) 0.70 (0.59 to 0.79) 1248 / 1338 / 14 0.50 (0.17 to 0.97) High risk of bias
Oral Cytology 0.91 (0.81 to 0.96) 0.91 (0.81 to 0.95) 1507 / 1575 / 12 ¹ 0.43 (0.27 to 0.69) High risk of bias
Light-based 0.91 (0.77 to 0.97) 0.58 (0.22 to 0.87) 1021 / 1165 / 11 ² 0.21 (0.04 to 0.73) High risk of bias
Vital Stain plus adjunct Not possible ³ Not possible ³ 402 / 478 / 6 ³ 0.27 (0.04 to 0.48) High risk of bias
1 Included in the meta-analysis (Remmerbach 2009 not included).
2 Included in the meta-analysis (Awan 2011 not included, which performed two index tests).
3 Insufficient studies to perform meta-analysis, data presented identifies numbers included in the review.
4 High risk of bias: inappropriate exclusion of patients (Du 2007; Upadhyay 2011), selecting patients (Onofre 2001) and excluding
patients from analysis (Warnakulasuriya 1996).
5 High risk of bias: inappropriate exclusion of patients (Sciubba 1999; Svirsky 2002; Navone 2004; Scheifele 2004; Seijas-Naya 2012),
index and reference test conducted simultaneously (Navone 2008), conflict of interests (Ng 2012; Scheifele 2004; Sciubba 1999; Svirsky
2002), time between index and reference test greater than two weeks (Scheifele 2004; Seijas-Naya 2012).
6 High risk of bias: excluding patients from analysis(Awan 2011; Awan 2012; Sharwani 2006b), inappropriate exclusion of patients
(Farah 2012; Scheer 2011).
7 High risk of bias: inappropriate exclusion of patients (Epstein 2008; Mehrotra 2010; Ujaoney 2012), conflict of interests (Epstein 2008),



































































































































D I S C U S S I O N
Summary of main results
Our review aimed to estimate the accuracy of index tests for the de-
tection of oral cancer and potentially malignant disorders (PMDs)
of the lip and oral cavity in patients presenting with clinically ev-
ident lesions. There were studies available to assess three diagnos-
tic technologies, namely, vital staining, cytology and light-based.
Despite all being undertaken in secondary care facilities, the stud-
ies showed diversity in geographic location, prevalence of disease,
relative skill level of practitioners, outcomes assessed and thresh-
olds used. However, a sufficient number of studies were identified
to proceed with meta-analysis. The methodological quality of the
studies was assessed to be poor overall, with no single study being
at low risk of bias across all the domains of the risk of bias.
The estimates of sensitivity and specificity for cytology were the
highest of the three health technologies assessed (summary sensi-
tivity 0.91 and specificity 0.91). This overall high level of test ac-
curacy requires careful interpretation. When expert clinicians en-
counter patients with PMDs they initiate a diagnostic algorithm,
procure tissue and submit it for histopathologic evaluation to ren-
der a definitive diagnosis. This is the established gold standard
for the diagnosis of oral epithelial dysplasia and oral squamous
cell carcinoma (OSCC). Indeed, when such an algorithm involves
clinicians with expertise in the diagnosis of oral mucosal diseases
who are experienced in performing minimally invasive biopsies
with optimal site selection, and is coupled with tissue interpreta-
tion by expert pathologists, it provides a very efficient pathway to
an accurate diagnosis. Yet, unfortunately, such clinicians are gen-
erally not the frontline clinicians who initially encounter patients
with PMDs. As such, the prism though which these adjunctive
technologies are interpreted must be considered. The high accu-
racy of cytology we report is based on studies predominantly per-
formed by such experts in cohorts with a higher percentage of dys-
plastic or malignant lesions than would be expected in a general
population. Indeed, the strong correlation between the cytological
samples that are procured from the same site(s) that are biopsied
should not be a surprise. Yet, current cytologic test outcomes can-
not discriminate between epithelial dysplasia or OSCC, therefore
still necessitating a tissue biopsy to reach a definitive diagnosis. As
such, experts would usually not employ cytology as a replacement
for tissue biopsy, at least not for a baseline assessment. The value
of cytology for use as a surveillance test by expert clinicians in
high-risk patients with a history of epithelial dysplasia or OSCC
for whom multiple serial biopsies are problematic has not been
adequately studied. The question remains, could cytology have
utility in the hands of non-expert frontline clinicians? Unfortu-
nately, our review cannot adequately answer this question. The
prevalence of PMDs in the general population is relatively high
compared to the known incidence of OSCC and therefore most of
the PMDs detected likely represent low-grade disease with a low
risk for malignant transformation. Frontline clinicians are there-
fore more likely to encounter low-risk lesions rather than lesions
that represent high-grade dysplasias orOSCC.Given the relatively
high sensitivity of cytology, the triage of low-risk lesions in the
general population with a non-invasive cytological test indicated
for lesions that are small enough to be adequately sampled seems
reasonable, although with some provisos. Clinicians must appre-
ciate that cytologic tests are not indicated for persistent epithelial
lesions for which a clear aetiology is unapparent and which display
one or more high-risk clinical features (e.g. induration, pain, ul-
ceration and/or heterogeneous white, red or mixed red and white
components) suggesting the possibility of variable histopathology
within the lesion field and increased risk for sampling errors by a
single brush. Such lesions are better referred to experts. Further-
more, they must be cognisant that cytology is imperfect and that
both “false positives” and “false negatives” are possible, therefore
surveillance and repeat sampling may be necessary. Studies investi-
gating the cost-effectiveness of cytology compared to referral have
not been performed. This is particularly relevant in resource-poor
countries where the role of non-invasive cytologic tests could be
performed by non-clinicians.
Light-based technologies (summary sensitivity 0.91 and specificity
0.58) are hampered by their low specificity. Frontline clinicians
relying on these technologies to dictate whether or not to rec-
ommend a biopsy or refer a patient for biopsy would result in
more than 40% of patients receiving unnecessary referral/treat-
ment. There is toomuch “noise” associatedwith these technologies
that will confuse the non-expert clinician. Filtering the “noise” by
gaining an appreciation for differentiating benign “confounder”
lesions from PMDs (e.g. lichen planus, erythematous candidiasis,
pigmented lesions and others) could bolster the specificity, but
studies assessing these technologies in the hands of frontline clin-
icians are lacking.
Vital staining technologies (summary sensitivity 0.84 and speci-
ficity 0.70) are hampered by suboptimal sensitivity and specificity.
The utility of vital staining should be confined for use by ex-
pert clinicians to facilitate biopsy site selection in heterogeneous
PMDs, or as a surveillance tool.
The potential for vital staining and light-based detection to be used
as a screening tool for detecting OSCC and PMD in apparently
healthy individuals warrants further investigation (U.S. Preventive
Services Task Force 2013;Walsh 2013), but, to date, none of these
have actually been used as a screening intervention (Brocklehurst
2013) and the cost-effectiveness of using these methods over and
above a visual screen would need to be justified. The concept of
combining technologies to improve test accuracy seems reason-
able; however, it is not possible to support the combining of such
tests as the data from this review were limited; more studies are
needed.
Ideally, the role of adjunctive tests is to reduce uncertainty in
the diagnostic decision. With some tests this can be achieved by
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exploring different threshold levels. However, this is not possible
with any of these tests as they all dichotomise patients as either
diseased or healthy. As a result, threshold analysis and area under
the curve could not be investigated.
Strengths and weaknesses of the review
A strength of the review is the number of included studies (41)
and the large amount of data that was evaluated (4314 lesions).
This enabled a series of meta-analyses to be undertaken and, given
the relative consistency in the classification of the target condition,
the potential for an accurate estimation of summary points was
considered to be high.
The review also identified a number of different categories of index
test, each of which contained sufficient data to estimate summary
values of sensitivity and specificity with an acceptable degree of
precision. A further strength of this review was the ability to de-
termine the relative diagnostic test accuracy between the different
index tests. However, the prevalence across the subgroups varied
from 4% to 97% and there was additional heterogeneity in the
eligibility criteria used, which makes a direct comparison more
problematic. For example, one study (Epstein 2008) included an
oral examination as part of the recruitment of patients to the study,
which may have introduced bias to the selection process by allow-
ing the selection of high-risk patients who are potentially more
straightforward to diagnose.
As the target condition can also affect a broad area of oral mu-
cosa, differences between the index test and reference standard
could also have been caused by differences in the location of the
respective tests. In many of the vital staining and light-based stud-
ies, it was not clear how clinicians determined the most appro-
priate location of the biopsy. For some of the studies, the basal
and transepithelial cell harvesting and potential ulceration caused
during procurement of a cytological sample might also have made
it challenging to undertake the reference standard in the same lo-
cation as the index test.
Applicability of findings to the review question
There were few concerns regarding the applicability of individual
studies to the address the review question. The study setting, pa-
tient selection, test conduct and interpretation were appropriate
for the purposes of the review. The concerns raised were a result of
inadequate reporting of the study index and reference test meth-
ods.
The findings are generalisable to the wider population due to the
geographical diversity of the included studies with one proviso
being that no studies originated inAfrica. Furthermore, the studies
focus on the performance of the adjunctive tests in a secondary
care facility, so the findings should be treated with caution when
considering primary care.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
None of the adjunctive tests can be recommended as a replace-
ment for the currently used standard of a scalpel biopsy and histo-
logical assessment. Yet, the performance of cytology compared to
histopathology shows promise; however, there is insufficient evi-
dence of the value of vital staining and cytology combined. Pa-
tients should be referred to clinicians with appropriate interest and
training in the management of PMD, including oral medicine,
oral and maxillofacial pathology, oral and maxillofacial surgery,
stomatology and head and neck surgery.
The index tests were conducted in secondary care with trained and
experienced specialists; no current evidence exists for their use in
primary care (Epstein 2008). Vital staining and light-based tests
are dependent on the visual assessment of the lesion (Mehrotra
2010) and cytology requires adequate training and experience of
correctly harvesting basal cells from the oral mucosa.
Implications for research
The overall quality of the included studies was poor, so there is
a need for further standardisation of research in this area to re-
duce bias. Diagnostic test accuracy (DTA) studies addressing this
area of research would be welcomed, particularly those that report
on a patient basis and that follow the STARD checklist (Bossuyt
2003) for reporting of diagnostic test accuracy studies. All new
DTA studies should ensure that they fully address the domains
within the QUADAS-2 tool (Whiting 2011). Patients should be
recruited consecutively or randomly prior to any oral examination
to avoid the potential for selection bias; training and calibration
of examiners should be clearly explained; the methods and tim-
ings of the reference standard should be clearly reported; and an
accepted classification of the target condition used. The numbers
of true positives, true negatives, false positives and false negatives
should also be clearly reported. The positivity threshold that has
been most consistently applied throughout these studies is where
OSCC and any form of dysplasia are treated as a positive diag-
nosis. The review group would urge further research to explore
whether this diagnostic threshold is commensurate with our evolv-
ing understanding of carcinogenesis as a non-linear process and
that grade of dysplasia may not be reliably predictive of malignant
transformation.
Given the relatively high values of the summary estimates of sen-
sitivity and specificity for cytology, this would appear to offer
the most potential. Combined adjunctive tests involving cytology
would warrant further investigation, only two studies investigated
vital staining plus cytology (Gupta 2007; Guneri 2011) and no
studies currently combine cytology with a light-based test. Studies
should endeavour to publish test results in as much detail as possi-
ble, the following categories are suggested as a minimum: benign,
mild, moderate, severe dysplasia and OSCC. This would allow
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further analysis to be undertaken to assess the severity of any mis-
diagnosis; if an OCSS is classified as a mild dysplasia by the index
test then the consequences are significantly more severe than if a
moderate dysplasia be classified as mild.
This review revealed some novel cytologic platforms. Remmerbach
2009 demonstrated the potential for new analysis methods such as
AgNOR, whileNg 2012 reported the use of quantitative DNA cy-
tology to maximise cytology. As the complexities of carcinogenesis
are revealed through a better understanding of genetic and epige-
netic alterations in PMDs, one might imagine the reality of plat-
forms employing real-time cytology (i.e. chairside results) where
morphological parameters are coupled with “predictive” biomark-
ers that can identify early lesions with a high risk for malignant
transformation.
The diagnostic potential of blood and saliva analysis should also
be investigated. Despite preliminary work being completed in this
area (Li 2004; Park 2009), study designs have so far been restricted
to case-control studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allegra 2009
Study characteristics
Patient sampling Method of patient selection: Quote “The study focuses on 45 oral mucosa lesions from 32 patients
(13 female, 19 male, mean age 59 years, range 42-82), coming under observation at theDepartment
of Otolaryngology- Head and Neck Surgery, at the University of Catanzaro.”
Patient characteristics and set-
ting
Age: mean age 59 (range 42-82)
Sex: 13 female, 19 male
SES: not reported
Ethnicity: not reported
Stated Risk Factors: none stated
Number of patients/lesions: 32/45
Lesion site: Quote “The site of the lesion was tongue in 11 cases, buccal mucosa in 9, floor of the
mouth in 8 and hard or soft palate in 4.”
Severity: non-neoplastic (hyper-keratoses, hyper-para-keratoses, etc), mild dysplasia, moderate dys-
plasia, severe dysplasia, in situ carcinoma, invasive carcinoma
Country: Italy
Type of facility: Department of Otolaryngology- Head and Neck Surgery, at the University of
Catanzaro
Prevalence: 30/45 lesions were premalignant or malignant
Index tests Category: Vital staining - Toluidine Blue
Description: Quote “Patients rinsed the oral cavity with water for 20 sec. to remove debris prior to
rinsing with 1% acetic acid for 20 sec. Toluidine blue (1% W/W) was applied as an oral rinse for
20 sec. and then 1% acetic acid was used for 20 sec to eliminate mechanically retained stain.”
Positivity threshold: Quote “Lesions that showed dark blue staining were considered to be positive
for premalignant or malignant tissue, while those with light staining, or totally not coloured, were
considered negative.”
Sequence of tests: Staining followed by reference standard.
Training or calibration of clinicians: No training reported.
Blinding of examiners: Index test completed before reference standard.
Multiple tests: No
Method of site selection: TB rinse - no site selection
Conflict of interests: Not stated
Target condition and reference
standard(s)
Category: Biopsy (punch) with histopathologic assessment
Description: Quote: “The biopsies were performed under local anaesthesia by punch biopsy, all
specimens were labelled with a progressive number and in a separate book, for each specimen the
clinical examination and the result of the toluidine blue staining were reported.”
Positivity threshold: Quote: “Histopathologic diagnoses were referred as: non-neoplastic (hyper-
keratoses, hyper-para-keratoses, etc), mild dysplasia, moderate dysplasia, severe dysplasia, in situ
carcinoma, invasive carcinoma”
Sequence of tests: Index test followed by reference standard
Training or calibration of pathologists: Not stated
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Allegra 2009 (Continued)
Blinding of examiners: Index test completed before reference standard. Quote: “The pathologist
examining all the biopsies was not informed regarding the clinical or staining evaluation of each
sample.”
Multiple tests: No
Method of site selection: Unclear
Target condition: Precancerous and cancerous oropharyngeal and oral cavity lesions
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Within same appointment so minimal interval.




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
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Allegra 2009 (Continued)
Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote: “One hundred and sixty-four consecutive patients aged over 16
years presenting in oral medicine clinics at two London hospitals with white, red, and mixed white
and red patches were invited to participate in the study. One hundred and twenty-six patients (76.
8%) consented andwere investigated by a standard protocol that involved clinical visual examination
and autofluorescence examination followed by biopsy.”
Of the 126 patients 116 received the reference test.
Patient characteristics and set-
ting
Setting: Secondary care, oral medicine clinics
Age: Over 16
Sex: Male 70 (55.6%); Female 56 (44.4%)
SES: Not reported.
Ethnicity: White 76 (60.3%); Non-white 50 (39.7%)
Stated Risk Factors:
Smokers 61 (48.4%); Ex-smoker 28 (22.2%); never smoked 37 (29.4%)
Alcohol: Current user 92 (73%); Ex-user 8 (6.4%); Never used 26 (20.6%)
Number of patients/lesions: 126/126, 10 did not received reference test
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Awan 2011 (Continued)
Lesion site: Buccal mucosa 54 (42.9%), Tongue 40 (31.7%), Floor of mouth 14 (11.1%), Palate
11 (8.7%), Alveolar ridge 7 (5.5%)
Severity: Unclear prior to testing, described as “with white, red, and mixed white and red patches”
Country: UK
Type of facility: Oral medicine clinic at two hospitals
Prevalance: Dysplastic: 44/116 (VELScope & Vizilite),
Index tests Index test 1 - VELScope
Category: Light based
Description: Themain lesionwas selected and diagnosed by consensus of two experienced examiners
after comprehensive clinical examination, photographed then examined with the VELscope
Quote: “under dimmed room light, with protective eye wear worn by the patient throughout the
procedure.”
Positivity threshold: Quote: “The possible outcome of the autofluorescence examination was deter-
mined by the manufacturer’s literature i.e. FVL - fluorescence visualization loss, FVR - fluorescence
visualization retained and FVI - fluorescence visualization increased”
Sequence of tests: VELScope then ViziLite then Toluidine blue, followed by reference standard
Training or calibration of clinicians: Calibrated by an experienced professional from the manufac-
turer, no results reported
Blinding of examiners: Index test examiners blind to reference test results.
Multiple tests: Yes; conducted independently during the same session, by the same examiners.Order:
VELScope, ViziLite, Toluidine Blue
Method of site selection: Principle area ofmorphology decided by consensus after visual examination
Conflict of interests: Equipment provided by LED Diagnosis who manufacture and market the
VELScope
Index test 2 - ViziLite
Category: Light based
Description: Chemiluminescent light source adjunct to oral examination quote “The oral cavity
was rinsed with 1% acetic acid solution prior to examination with the ViziLite”
Positivity threshold: Quote “lesions that showed an aceto-white appearance under the chemilumi-
nescent light”
Sequence of tests: VELScope then ViziLite then Toluidine blue, followed by reference standard
Training or calibration of clinicians: 2 clinicians, 1 of whom was an experienced examiner. No
reporting of training or calibration by demonstration of kappa score, although does report that COE
findings, the area for further examination identified, and findings using ViziLite were all verified
and consensus found between the 2 clinicians
Blinding of examiners: Index test examiners blind to reference test results.
Multiple tests: Yes; conducted independently during the same session, by the same examiners.Order:
VELScope, ViziLite, Toluidine Blue
Method of site selection: Quote: “The principal area (site) of morphologically altered mucosa
excluding any ulcerated areas (by consensus of both examiners) was selected and photographed. All
further investigations were performed on this clinically detected area of mucosal abnormality.”
Conflict of interests: Equipment provided by manufacturers and marketers of ViziLite quote
“ViziLite kits for the study were supplied by Zila Inc.”
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote: “A surgical biopsy was performed for histopathological assessment...the pres-
ence or absence of dysplasia was further reviewed by an experienced oral pathologist.”
Positivity threshold: Quote: “The presence or absence of dysplasia in the biopsy specimen was
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Awan 2011 (Continued)
recorded by an experienced oral pathologist”
Sequence of tests: Index tests followed by reference standard
Training or calibration of pathologists: Only one experienced pathologist.
Blinding of examiners: Quote: “A surgical biopsy of the clinically altered area was performed for
histopathological assessment, and after formal diagnostic reporting by two pathologists (blinded
to ViziLite data), the presence or absence of dysplasia was further reviewed by an experienced oral
pathologist.” each index test reported separately, quote taken from Vizilite paper, but not clarified
in other paper
Multiple tests: No
Method of site selection: The index test results were used to inform the selection of biopsy site
Target condition: Dysplasia
Flow and timing Patients receiving index test but not reference test: 10
Patients receiving reference test but not index test: 0
Time interval: the tests were conducted independently (though on the same session for patient
convenience)
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes Index test - VELScope & Vizilite: Only able to report on 116 patients that received reference test
Papers report data on leukoplakia and erythroplakia (through clinical diagnosis only), only data
reporting dysplastic or non-dysplasia from pathology used
Results published for Vizilite are misprinted in the journal article, 72 classed as “other”, made up
of 52 aceto-white and 20 normal. Confirmed by author
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
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Awan 2011 (Continued)
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Consecutive patients presenting in oral medicine clinics at two London
Hospitals, with white, red and mixed white and red patches
Patient characteristics and set-
ting
Setting: Secondary care, oral medicine clinics
Age: Over 16
Sex: Male 61%; Female 39%
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Awan 2012 (Continued)
SES: Not reported.
Ethnicity: White 67%; Non-white 33%
Stated Risk Factors:
Smokers 52%; Ex-smoker 22%; never smoked 26%
Alcohol: Current user 79%; Ex-user 6%; Never used 15%
Number of patients/lesions: 92/92
Lesion site: Buccal mucosa 37%, Tongue 33%, Floor of mouth 11%, Palate 11%, Alveolar ridge
9%
Severity: Unclear prior to testing, described as “with white, red, and mixed white and red patches”
Country: UK
Type of facility: Oral medicine clinic at two hospitals
Prevalance: 41/92
Index tests Category: Vital staining
Description: Quote “TBlue staining test was performed using the TBlue oral lesionmarking system.
... The TBlue kit consisted of three swab tubes: Swab tube1, 1% acetic acid solution (pre rinse swab)
, Swab tube 2, 0.5% tolonium chloride solution and Swab tube 3, 1% acetic acid solution (post
rinse swab). The staining procedure was carried out according to the manufacturer’s instructions.”
Positivity threshold: positive result: stained dark or light blue; negative result: no stain
Sequence of tests: VELScope then ViziLite then Toluidine blue followed by the reference test
Training or calibration of clinicians: not discussed
Blinding of examiners: not discussed
Multiple tests: Yes; conducted independently during the same session, bu the same examiners.Order:
VELScope, ViziLite, Toluidine Blue
Method of site selection: visual examination by two examiners
Conflict of interests: Equipment provided by manufacturers and marketers of Toluidine Blue kits,
Zila Inc
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote: “A surgical biopsy was performed for histopathological assessment...the pres-
ence or absence of dysplasia was further reviewed by an experienced oral pathologist.”
Positivity threshold: Quote: “The presence or absence of dysplasia in the biopsy specimen was
recorded by two experienced oral pathologists”
Sequence of tests: Index tests followed by reference standard
Training or calibration of pathologists: Two experienced pathologists.
Blinding of examiners: Unclear
Multiple tests: No
Method of site selection: The index test results were used to inform the selection of biopsy site
Target condition: Dysplasia
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: the tests were conducted during the same session for patient convenience
Patients receiving both index and reference test but excluded from analysis: 24 patients receive
toluidine blue test and reference test but were excluded from analysis, because of the characteristics
of their lesions - patients with mixed red and white lesions were excluded from the analysis
Comparative
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: ”One hundred and sixty patients referred to the Department of Oral
Medicine, Faculty of Dentistry, Complutense University of Madrid, Spain were selected for this
study.“ ”patients presented with 160 mucosal lesions, which required biopsy evaluation“
Patient characteristics and set-
ting
Age: 55.3 +- 16.1 years, range 13-100 years
Sex: 77 men 83 women
SES: not reported
Ethnicity: All Caucasian
Stated Risk Factors: 34% smokers, 27% consumed alcohol regularly
Number of patients/legions: 160/160
Lesion site: Oral cavity
Severity: Quote ”subjects with benign lesions or clinically suspicious pre-malignant or malignant
lesions that were either white or red, exophytic or presenting as non-healing ulcers’
Country: Spain
Type of facility: Secondary
Prevalance: 29/160
Index tests Category: Vital staining - Toluidine Blue
Description: Quote “Toluidine Blue was applied as a mouth rinse using the protocol described by
Mashberg, with 1% aqueous acetic acid applied initially as a mucolytic agent and after Toluidine
Blue rinsing to remove excess stain”
Positivity threshold: Quote “The stain was considered positive when the surface mucosa took on
a blue colour, either if the entire lesion was stained or just a portion of it. Those that do not took
colouration or with equivocal findings were considered negatives”
Sequence of tests: Index followed by reference
Training or calibration of clinicians:Quote “aworking clinical diagnosis was established usingWHO
Criteria 1980”, quote “The test outcome was subjected to clinical evaluation, by four experienced
oral pathologists previously calibrated in pairs.”
Blinding of examiners: Index completed prior to reference.
Multiple tests: No
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Cancela-Rodriguez 2011 (Continued)
Method of site selection: Toluidine Blue rinse so no site selection
Conflict of interests: Not reported.
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Biopsy method unclear
Positivity threshold: Quote “Following histopathological diagnosis, all lesions were classified in two
groups: non-dysplastic nonmalignant lesions, when there were no signs of dysplasia or histological
malignancy and dysplastic malignant lesions, when dysplasia or invasion was present.”
Sequence of tests: Index followed by reference
Training or calibration of pathologists: Quote “To avoid any inter examiner variability, the biopsies
from this study were evaluated by the same pathologist to determine the presence and degree of
dysplasia, or malignancy”
Blinding of examiners: Unclear whether the same pathologist evaluates the index and reference test
Multiple tests: No
Method of site selection: Quote “For lesions with a positive toluidine test, the biopsy was taken
from the stained area”
Target condition: Dysplasia or histological malignancy
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Quote “biopsy was taken from the stained area” so during the same appointment




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
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Cancela-Rodriguez 2011 (Continued)
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote “Fifty-eight patients who presented with suspected oral lesions
were recruited into the study.”
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Chen 2007 (Continued)
Ethnicity: not reported
Stated Risk Factors: quote “About two-thirds of cases consisted of smokers or people who chewed
betel nuts”
Number of patients/lesions: 58 patients and lesions
Lesion site: Oral cavity
Severity: quote “The lesions were characterised as homogeneous leukoplakia, heterogeneous leuko-
plakia, erythroplakia, and ulceration”
Country: Taiwan
Type of facility: Secondary
Prevalance: (cancer or precancerous) 29/58
Index tests Category: Vital staining - methylene blue
Description: Quote “A standard staining procedure included gargling with rinsing solution (1%
lactic acid in purified water flavoured with raspberry) for 20s, subsequently after power air spray on
the lesion, the dye was given by gargling methylene blue (1% malachite, 1% eosin, 0.5% glycerol
and dimethyl sulphoxide) for 20s followed by an additional 20s of gargling with the rinsing solution.
”
Positivity threshold: unclear
Sequence of tests: Index followed by reference
Training or calibration of clinicians: Not reported. Quote “The pattern and intensity of the staining
was recorded and supervised by an experienced oral surgeon.”
Blinding of examiners: Index completed prior to reference.
Multiple tests: No
Method of site selection: Methylene rinse so no site selection
Conflict of interests: Quote “grant supported by NSC-94-2314B075 and VGH94242C”
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Biopsy method unclear
Positivity threshold: Quote “Following histopathological diagnosis, all lesions were classified in two
groups: non-dysplastic nonmalignant lesions, when there were no signs of dysplasia or histological
malignancy and dysplastic malignant lesions, when dysplasia or invasion was present.”
Sequence of tests: Index followed by reference
Training or calibration of pathologists: Quote “The pathological diagnosis was examined and verified
independently by two specialists” Unclear
Blinding of examiners: Examinations were independent
Multiple tests: No
Method of site selection: Quote “The most obviously stained area or the most suspicious looking
area , if there was no update of dye, was biopsied.”’
Target condition: Dysplasia and squamous cell carcinomas
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Completed at the same time
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Unclear
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Any patients with mucosa lesion referred to College of Stomatology,
Sun Yat-sen University between Oct 2000 and March 2001 were included
Patient characteristics and set-
ting
Age: 58.3 (range 7-76)
Sex: male 11%, female 89%
SES: not reported
Ethnicity: not reported
Stated Risk Factors: not reported
Number of patients/lesions: 60/60
Lesion site: Mainly on buccal and lingual areas
Severity: Not stated
Country: China
Type of facility: College of Stomatology , Sun Yat-sen University
Prevalance: 54/60
Index tests Category: Vital staining - Oratest
Description: Oratest staining - similar to toluidine blue. Use the pre-exam mouthwash fluid for 20
seconds, wash the mouth twice with water, then use 1% toluidine blue to wash the mouth for 20
seconds and then wash the mouth with water twice, then use another mouthwash fluid (not clearly
described) for 30 seconds. For the topical application group, 1% toluidine blue was used topically
without mouth washing
Positivity threshold: Blue staining of the lesion predict a positive outcome, blurred blue staining
which could not be washed out by the mouthwash fluid was also considered as positive
Sequence of tests: Before pathological test
Training or calibration of clinicians: No training reported
Blinding of examiners: Index test completed before reference standard.
Multiple tests: No
Method of site selection: not reported
Conflict of interests: not reported
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Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Scalpel biopsy-based pathology, no further description provided
Positivity threshold: not reported
Sequence of tests: Index then reference test
Training or calibration of pathologists: not reported
Blinding of examiners: not reported
Multiple tests: no
Method of site selection: not reported
Target condition: Oral cancers and epithelial dysplasia
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: not clear




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-
ers undertaken and results re-
ported?
Unclear
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Wheremultiple index testswere
used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes





Patient sampling Second entry created for Cheng 2003, the 60 patients were split into two groups, one used a topical
application and the other a rinse. To allow for covariate analysis a second entry is necessary to split
the data for the results
Patient characteristics and set-
ting
Index tests
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Did the study avoid inappropri-
ate exclusions?
DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Was calibration of examin-
ers undertaken and results re-
ported?
Wheremultiple index testswere
used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Did all patients receive the same
reference standard?




Patient sampling Method of patient selection: Quote “study group consisted of 25 patients with 26 lesions which
had been visited from Oct 2005 to Jan 2007, at Oral Medicine of Mashhad Faculty of Dentistry
and Otorhinolaryngology Department of QAEM, IMAM, REZA and OMID hospitals, Mishhad,
Iran.”
Quote “Inclusion criterion was: lesions clinically diagnosed as oral potentially malignant (leuko-
plakia, OLP) or malignant lesions (OSCC and verrucous carcinoma) and requiring an incisional
biopsy for definite diagnosis.”
Patient characteristics and set-
ting
Age: 54.00 ± 17.38
Sex: 13 men 12 women
SES: Not reported
Ethnicity: Not reported
Stated Risk Factors: unclear
Number of patients/lesions: 25/26
Lesion site: Oral cavity
Severity: quote “lesions clinically diagnosed as oral potentially malignant (leukoplakia, OLP) or
malignant lesions (OSCC and verrucous carcinoma) and requiring incisional biopsy for definite
diagnosis”
Country: Iran
Type of facility: Secondary
Prevalance: (dysplasia /malignancy) 8/26
Exclusions: history of any treatment for the lesion, systemic contraindication for scalpel biopsy
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Index tests Category: Cytology - OralCDx (lab processing not performed at OralCDx lab)
Description: Quote “After determination of site biopsy, under local anaesthesia, needed for scalpel
biopsy, the Oral CDx brush was placed in the selected area and turned 5 to 10 times until appearing
pinpoint bleeding-upon manufacture’s recommendation.”
Positivity threshold: Quote “The pathological findings were categorized as three groups: 1) Positive:
dysplastic epithelial changes 2) Negative: absence of any evidence suggesting dysplasia 3) Inadequate
sampling”
Sequence of tests: Index followed by reference
Training or calibration of clinicians: Unclear. quote “They were examined by a pathologist informed
about clinical diagnosis”
Blinding of examiners: Index completed prior to reference, quote “blind to the histopathological
results”“
Multiple tests: No
Method of site selection: Quote ”The most impressive site of biopsy was determined upon one if
these criteria: 1) The most probable site of dysplasia/malignancy OR 2) High risk area for dysplasia/
malignancy OR 3) The most surgically accessible site“
Conflict of interests: University support acknowledged.
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Scalpel biopsy method unclear.
Positivity threshold: Quote ”The Pindborg criteria for detecting dysplasia andmalignancy were used
and the histopathologic diagnosiswasmade.The presence of dysplasia/malignancy in histopathology
was classified as normal , mild, moderate and severe dysplasia (level 1 to 3), carcinoma In Situ (level
4) and carcinoma (level 5).“
Sequence of tests: index followed by reference
Training or calibration of pathologists: unclear
Blinding of examiners: Quote ”The histopathologic preparations were observed by the same pathol-
ogist blind to the cytopathical study and informed about clinical diagnosis“
Multiple tests: not applicable
Method of site selection: Quote ”The scalpel biopsy was done immediately in the site of pin-point
bleeding.“
Target condition: Quote ”The Pindborg criteria for detecting dysplasia and malignancy were used
and the histopathologic diagnosiswasmade.The presence of dysplasia/malignancy in histopathology
was classified as normal , mild, moderate and severe dysplasia (level 1 to 3), carcinoma In Situ (level
4) and carcinoma (level 5)
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Not discussed
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes Assumed figures in Table 2 should be reversed: “Gold Standard” Normal and Disease should be
reversed. This has been done for data entry
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: 132 patients from School and Hospital of Stomatology, Wuhan Uni-
versity, between July 2002 and November 2003
Inclusion criteria for patients:
(i) superficial ulceration suspicious of malignancy
(ii) oral leukoplakia
(iii) oral lichen planus
(iv) oral leukokeratosis
Excluded:
(i) benign oral lesion
(ii) lesion without histological result after clinical diagnosis
Patient characteristics and set-
ting
Age: Mean 49.4 SD 12.7
Sex: 67 female, 61 male
SES: not specified
Ethnicity: not specified
Stated Risk Factors: not discussed
Number of patients/lesions: 128/128
Lesion site: Oral cavity
Severity: All patients suspected of malignancy, leukoplakia, lichen planus, leukokeratosis
Country: China
Type of facility: Secondary
Prevalance: 33/128
Index tests Category: Vital staining - Rose Bengal
Description:Quote ”(i) oral examinationof the location, size,morphology and surface characteristics
of the lesions, (ii) mouth rinse with distilled water (reagent A) to clean the lesions for 1 minute,
(iii) applications of solution of RB (reagent B) with cotton tip for 2 minutes, (iv) mouth rinse with
distilled water (reagent C) to remove excess RB solution for 1 minutes, (v) oral examination of the
location, size, morphology and surface characteristics of sites stained.“
Positivity threshold: Quote ”Staining result of a lesion was classified as 1, 2, 3 or 4 according to the
shade tabs. In the present study, staining results of 3 and 4 were regarded as RB positive staining,
while staining results of 1 and 2 were regarded as RB negative staining.’
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Du 2007 (Continued)
Sequence of tests: Unclear regarding ordering, implied that histology performed after index
Training or calibration of clinicians: Single clinician training not reported.
Blinding of examiners: Assume given implied sequence of tests.
Multiple tests:No
Method of site selection: Oral examination.
Conflict of interests: Grant sponsor, Science and Technology Bureau of Wuhan City, People’s Re-
public of China; Grant number: 20026002084, assume no conflict
Target condition and reference
standard(s)
Category:Biopsy with histopathologic assessment.
Description: Scalpel used, methods unclear.
Positivity threshold: Unclear reporting, but outcomes reported as either malignant (including dys-
plasia or squamous cell carcinoma) or benign
Sequence of tests: Unclear, but assumed after index from reporting structure.
Training or calibration of pathologists: none, only one experienced oral pathologist used.
Blinding of examiners: Blind to index test.
Multiple tests: No.
Method of site selection: Unclear but each patient had one lesion, assume biopsy taken from this
lesion
Target condition: Malignant or benign.
Flow and timing Patients receiving index test but not reference test: 4
Patients receiving reference test but not index test: 0
Time interval: Not specified




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
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Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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Epstein 2008
Study characteristics
Patient sampling Method of patient selection: Quote “Patients were identified in clinics at three study sites: the
University of California San Francisco (UCSF), the University of Illinois Chicago (UIC), and the
British Columbia Cancer Agency (BCCA)”
quote “Patients who had a history of oral lesions or were at high risk for an oral lesion were identified
and asked to participate.”
Patient characteristics and set-
ting
Age: mean = 59.4 (SD = 12.53)




Cigarette smokers: current 15.48%, prior 41.67%,
Alcohol consumers = two thirds,
Cigar/pipe/chew/snuff - less than 10%
No betel nut
Number of patients/lesions: 84/97
Lesion site: not reported, but was recorded by examiners
Severity: patients identified with a lesion on conventional visual examination
Country: US
Type of facility: secondary care
Prevalance: 42/97
Index tests Category: Vital staining plus adjunct - Vizilite and Toluidine Blue
Description: Lesions were identified by visual examination, acetic acid rinse applied for 30-60
seconds, then evaluated by chemiluminescent light, lesion then swabbed with acetic acid solution
followed by swabbing of Toluidine Blue, then a further swab of acetic acid
Positivity threshold: Quote “The investigator reported their subjective assessment of the impact of
chemiluminescence upon lesions characteristics of brightness, sharpness, surface texture, and/or size
using a four point Likert scale (decreased, no change, slight improvement, marked improvement)
. After the toluidine blue staining the investigator recorded the staining pattern either as negative,
incomplete, or complete total lesion staining.” Potential confusion over “incomplete”
Sequence of tests: Visual, light based, vital stain then reference test.
Training or calibration of clinicians: not discussed
Blinding of examiners: Not blind of other index tests, index test defined as the combination of light
based and vital stain
Multiple tests: Yes. Combined test results used (Table 4 Toluidine Blue) as authors report ’adjunct’
tests and cumulative values
Method of site selection: from oral examination.
Conflict of interests: funded by Trylon Corp, authors linked to Zila Inc.
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote “All visualized lesions were then biopsied using either scalpel or punch tech-
nique. All procedures were conducted within a single patient visit. Histopathologic diagnoses were
completed by board certified Oral Pathologists who were blinded to the clinical findings.”
Positivity threshold: Quote “serious pathology was selected to refer to severe dysplasia, CIS and
frank SCC. Benign (referring tomicroscopic evidence of no epithelial dysplasia), mild and moderate
dysplasias were classified as non-serious pathology for this analysis”
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Sequence of tests: index then reference
Training or calibration of pathologists: not discussed, although quote “board qualified oral pathol-
ogist”
Blinding of examiners: Yes
Multiple tests: No
Method of site selection: All lesions visualised during index test
Target condition: Severe dysplasia, CIS and SCC
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: minimal, completed on the same day
Patients receiving both index and reference test but excluded from analysis: 1 won’t have significant
effect on results
Comparative
Notes Concerns regarding this study analysis for cancer only, ignoring PMDs. Positive results include only
severe dysplasia. We have re-classified the reported data with a positivity threshold of mild dysplasia
and above. Results screened equivocally have been categorised as positive
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Unclear
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Yes
Was calibration of examin-
ers undertaken and results re-
ported?
No
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Wheremultiple index testswere
used were the results of the sec-
ond index test interpreted with-




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote ”Fifty five patients referred to an oral medicine specialist service
over a 3 month period for assessment of an oral mucosal white lesion were prospectively screened
with Vizi-Lite“
Patient characteristics and set-
ting
Setting: Oral medicine specialist, secondary care.
Age:Male 56.81 (2.2), female 58.7 (2.47)
Sex: Male 47%, Female 53%
SES:not discussed
Ethnicity:not discussed
Stated Risk Factors:21 smokers (38%)
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Farah 2007 (Continued)
Number of patients/lesions:55/80, only reported on primary lesions = 55
Lesion site:
Aleolar ridge: Primary 10 / Satellite 2
Tongue: 17 / 7
Buccal mucosa: 17 / 13
Floor of mouth: 5 / 1
Gingiva: 2 / 1
Palate: 2 / 1
Lip: 2 / 0
Severity: oral mucosal white lesion
Country: Australia
Type of facility: secondary
Prevalance: 10/55
Index tests Category: Light based - Vizilite
Description: Quote ”After a 60s rinse with 1% acetic acid solution, the outer flexible capsule of the
light stick was bent, breaking the inner fragile glass vial. The light stick was shaken vigorously to
mix the contents, and then placed in the open end of the retractor and assembled. The room and
operatory lights were dimmed, and the examination with ViziLite illumination was undertaken.“
Positivity threshold: Unclear, although the authors do state ”all lesions appeared “aceto-white” under
chemiluminescent light, and were considered ViziLite positive“ it is not clear that this detail was
used in the diagnostic decision
Sequence of tests: index then reference
Training or calibration of clinicians: Quote ”calibration amongst the two oral medicine specialists“
unclear whether this refers to the decision on the lesion or prior training/calibration
Blinding of examiners:unclear
Multiple tests: no
Method of site selection: Intra-oral examinations
Conflict of interests:none
Target condition and reference
standard(s)
Category:Biopsy with histopathological assessment
Description: Quote ”an incisional scalpel biopsy was performed under local anaesthesia to obtain a
definitive histopathological diagnosis’
Positivity threshold: taken from table 3, results of histology worked back to clinical definitions:
Homogenous leukoplakia/keratosis, Fibroepithelial hyperplasia, Oral lichen planus/lichenoid stom-
atitis,
Non-homogenous leukoplakia/epithelial dysplasia, Squamous cell carcinoma, Non-specific ulcera-
tion
Sequence of tests: index then reference
Training or calibration of pathologists: not discussed
Blinding of examiners: Quote “registered oral pathologists not involved with the clinical study”
Multiple tests: no
Method of site selection:not discussed
Target condition: see above
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Scalpel biopsy performed after clinical diagnosis
Patients receiving both index and reference test but excluded from analysis: 0
55Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Farah 2007 (Continued)
Comparative
Notes Quote “examination of the oral tissues with ViziLite illumination did not change the provisional
diagnosis, nor alter the biopsy site”
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Unclear
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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of the results of the index tests?
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote: “Patients presenting to an oral medicine specialist unit for
assessment of an oral mucosal lesion were recruited into the study” “Patients known to have oral
epithelial dysplasia or squamous cell carcinoma were not included in this study.”
Patient characteristics and set-
ting
Setting: Oral medicine specialist, secondary care
Age: Mean - Male 57.8 (+/- 11.88); Female 59.08 (+/- 12.8)





Alcohol consumer: 47/112, 42%
Smoker and alcohol consumer: 31/112, 27.7%
Number of patients/lesions: 112/118
Lesion site: oral cavity
Severity: Quote “oral mucosal white or mixed red/white lesion that was deemed [...] to be clinically
suspicious”
Country: Australia
Type of facility: Quote: “oral medicine specialist unit”
Prevalance: 27/118 (3/118 OSCC; 24/118 PMD)
Index tests Category: Light-based - VELScope
Description: Quote: “Clinical examination was repeated using VELScope while the room and
operatory lights were dimmed, and all measurements repeated.”
Positivity threshold: Quote: “Lesions that showed loss of autofluorescence were deemed positive,
and lesions that did not show any loss of autofluorescence were deemed negative. In addition, all
lesions that lost autofluorescence were blanched to evaluate diascopic fluorescence, and those that
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were deemed negative for loss of autofluorescence only if complete blanching was achieved.”
Sequence of tests: Index test followed by reference standard
Training or calibration of clinicians: Calibration of VELScope findings are reported, but no reporting
of training
Quote: “Clinical interobserver agreement was calculated with 71.4% agreement on the clinical
provisional diagnosis, 60.7% agreement on the VELScope provisional diagnosis, 82% agreement on
loss of autofluorescence, and 62% agreement on complete blanching after loss of autofluorescence.
”
Quote: “Calibration of clinical observations was also undertaken between 2 of the authors (C.S.F.
and M.J.M.) on a separate cohort of patients not included in this study.”
Blinding of examiners: Index test completed prior to reference standard. Nothing specifically re-
ported
Multiple tests: No
Method of site selection: visual examination
Conflict of interests: Not specifically reported.
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessments
Description: Quote: “A scalpel tissue biopsy was taken.”... “Biopsy specimens were fixed in formalin,
blocked in paraffin, stained with hematoxylineosin, and assessed by routine histopathology ”
Positivity threshold: Taken from table 4, results of histology worked back to clinical definitions
Sequence of tests: Index test followed by reference standard
Training or calibration of pathologists: Quote: “There was a 96.6% interobserver agreement for
histopathological interpretation between the 2 pathologists.”
Blinding of examiners: Quote: “Both examiners were blinded to the clinical findings”
Multiple tests: No
Method of site selection: Quote: “Loss of autofluorescence was used to determine the best site for
biopsy”
Target condition: Dysplasia and OSCC
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Not reported.




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
No
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Low
DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Study characteristics
Patient sampling Method of patient selection: Quote “Thirty-five patients with oral mucosal lesions identified by the
Orofacial Lesions Council of Ege University, Izmir, Turkey, were seen for further evaluation”
Patient characteristics and set-
ting
Age: mean 56.2 years
Sex: 13 men, 22 women
SES: not stated
Ethnicity: not stated
Stated Risk Factors: 47% smokers
Number of patients/lesions: 35/43
Lesion site: buccal mucosa 56%, tongue 19%, hard palate 14%
Severity: Quote “Lesions selected for further examination with Tblue staining and brush cytology
were homogenous and non-homogenous leukoplakia, reticular erosive/ulcerated lichenoid lesions,
and superficial ulcerations suspicious of malignancy”
Country: Turkey
Type of facility: University clinic
Prevalance: 15/43
Index tests Index Test 1: Toluidine Blue
Category: Vital staining
Description: Quote “head, neck and intraoral examinations were completed before Tblue applica-
tion, oral brush cytology and scalpel biopsy”
Toluidine BLue: quote “The oral rinsing protocol was: 20s pre-rinse with 30ml of 1% acetic acid;
20s water rinse; 20s rinse/gargle with 10 ml of the 1% tolonium chloride solution; 20s post-rinse
with 30ml of 1% acetic acid (twice); a final water rinse.”
Positivity threshold: Quote “The pattern of dye retention and the intensity of stain retention were
recorded (2, dark blue staining; 1, minimal blue staining; 0, no blue staining). Occasionally, normal
mucosa also appeared light blue, but this staining was not interpreted as positive.”
Sequence of tests: Staining, brush biopsy, followed by reference standard
Training or calibration of clinicians: not reported, although performed by one examiner
Blinding of examiners: Not specified.
Multiple tests: yesCombined test results used (Table 1) as tests not carried out independently; results
of first index test used to inform second index test
Method of site selection: not reported
Conflict of interests: stated no conflict and funded by University
Index Test 2: Brush Cytology
Category: Cytology - Cytobrush
Description: Quote “Brush cytology was performed using a Cytobrush Plus GT which was rotated
on the lesion site with pressure, until pinpoint bleeding was observed. The harvested cells were
transferred to a slide by a 3608 turning and rolling motion with the brush and the slides were
washed rapidly with ethyl alcohol for fixation. Cytology specimens were stained with hematoxylin-
eosin, and examined by an oral pathologist”
Positivity threshold: Quote “The brush cytology results were classified as malignant, atypical (sus-
picious), benign tissues or inadequate sample”
Sequence of tests: TB, brush biopsy, followed by reference standard
Training or calibration of clinicians: not reported
Blinding of examiners: Not specified.
Multiple tests: yesCombined test results used (Table 1) as tests not carried out independently; results
60Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Guneri 2011 (Continued)
of first index test used to inform second index test
Method of site selection: not reported
Conflict of interests: stated no conflict and funded by University
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote “All lesions were subject to scalpel biopsy with selection based on the clinical
appearance of the lesion.” “The scalpel biopsy specimens were submitted in formalin for hema-
toxylin-eosin staining. After embedding, 5 mm thick sections were prepared.”
Positivity threshold:Quote “Pathologic interpretation was based on established criteria and classified
as squamous cell carcinoma, epithelial dysplasia, hyperkeratosis, lichen planus, and other benign”.
..“biopsies confirmed as severe dysplasia, carcinoma-in-situ or SCC were considered ‘positive’; no
dysplasia, mild and moderate dysplasia were ‘negative”’
Sequence of tests: Index then reference
Training or calibration of pathologists: Quote “Surgical biopsies were performed by an experienced
oral and maxillofacial surgeon.”
Blinding of examiners: Not reported.
Multiple tests: One reference standard.
Method of site selection: Quote “All areas retaining Tblue were biopsied; in sites with no retention
of staining, clinical judgment guided the biopsy procedure.”
Target condition: ’Pathologic interpretation was based on established criteria (WHO) and classified
as squamous cell carcinoma, epithelial dysplasia, hyperkeratosis, lichen planus, and other benign
lesions.’
Flow and timing Patients receiving index tests but not reference test: 0
Patients receiving reference test but not index tests: 0
Time interval: not more than two weeks between the three methods of investigation
Patients receiving both index and reference test but excluded from analysis: one for brush biopsy
considered a false positive because of inadequate cell sampling
Comparative
Notes Toluidine Blue prepared as an oral rinse since there is no pharmaceutical grade Toluidine Blue
available in Turkey
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
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If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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Study characteristics
Patient sampling Method of patient selection: Quote: “96 patients with suspicious oral lesions who attended the
outpatients clinics of Otorhinolaryngology Department, Swaroop Rani Nehru Hosplial Allahabad,
were screened.”
Patient characteristics and set-
ting
Age: (benign and premalignant) 38, range 19-75 years; (Squamous Cell Carcinoma) 52, range 35-
74 years
Sex: (benign and premalignant) 42 men 22 women; (SCC) 24 men 8 women
SES: not reported
Ethnicity: not reported (India)
Stated Risk Factors: (benign and premalignant) 62% smokers, 66% chewed tobacco, 44% chewed
pan, 47% consumed alcohol regularly; (SCC) 23% smokers, 80% chewed tobacco, 83% chewed
pan, 19% consumed alcohol regularly
Number of patients/lesions: 96
Lesion site: Oral cavity
Severity: Quote “suspicious pre-malignant or malignant lesions of the oral cavity irrespective of site,
stage and sex were selected”
Country: India
Type of facility: Secondary
Prevalance: (premalignant and malignant) 46/96
Index tests Index Test 1: Toluidine Blue
Category: Vital staining
Description: quote “One percent aqueous toluidine blue was applied to suspicious lesion for 30
seconds. It was followed by a tap water or normal saline rinse. Then it was rinsed by 1% acetic acid
for 30 seconds to reduce background staining.”
Positivity threshold: Participants’ results classed as positive or negative but no thresholds or inade-
quate/equivocal results reported
Sequence of tests: Staining, brush biopsy, followed by reference standard
Training or calibration of clinicians: not reported
Blinding of examiners: Index completed prior to reference.
Multiple tests: yes. Combined test results used (Table 3 ) results of first index test used to inform
second index test
Method of site selection: not reported
Conflict of interests: not reported
Index Test 2: Brush Cytology
Category: Cytology
Description: Quote“Utilizing a small, hard toothbrush, a transepithelial biopsy was taken with
minimumdiscomfort to the patient. To obtain an adequate specimen,moderate pressure was applied
on the lesion by the brush until pinpoint bleeding was noted signalling entry into lamina propria
and thus signalling entry into the full thickness of the epithelium.”
Positivity threshold: Quote “The following parameters were analysed in the smear: enlarged nuclei,
variation in nulear size and shape (pleomorphism), nuclear borders, nuclear/cytoplasmic ratio, num-
ber of nuclei, hyperchromatism, chromatin patter and distribution, and discrepancy in maturation.
” Participants’ results classed as positive or negative but no thresholds or inadequate / equivocal
results reported
Sequence of tests: TB, brush biopsy, followed by reference standard
Training or calibration of clinicians: not reported
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Blinding of examiners: Index completed prior to reference. Not reported whether results of TB
staining were known prior to biopsy
Multiple tests: yes. Combined test results used (Table 3 ) results of first index test used to inform
second index test
Method of site selection: not reported
Conflict of interests: not reported.
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote “For histology, after routine processing and paraffin embedding, several sections
(3-4 mm in thickness) were cut from each case. At least 1 section of each case was stained with
hematoxylin-eosin and examined for histological diagnosis.”
Positivity threshold: Results reported as SCC, Dysplasia or benign.
Sequence of tests: both index tests were followed by reference standard.
Training or calibration of pathologists: not reported.
Blinding of examiners: not reported
Multiple tests: no
Method of site selection: not reported
Target condition: benign (including oral submucous fibrosis and angiomatous malformation), pre-
malignant (dysplasia) and squamous cell carcinoma
Flow and timing Patients receiving index tests but not reference test: 0
Patients receiving reference test but not index tests: 0
Time interval: not reported
Patients receiving both index and reference test but excluded from analysis: 0
All patients had toluidine blue staining, oral brush biopsy and scalpel biopsy
Comparative
Notes Exclude brush biopsy as an independent index test (blue staining present) and only use results for
toluidine blue staining and combined index test of staining and brush biopsy. Numbers for TP, FP,
TN, FN have been calculated from raw data presented in table III sensitivity and specificity values.
Results have been entered for both premalignant and malignant
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
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If a threshold was used, was it
pre-specified?
Unclear
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Study characteristics
Patient sampling Method of patient selection: Quote “All patients attended the Maxillofacial Surgery Clinic at the
UniveristyHospital inMainz,Germany andwere examinedbetweenSeptember 2005 andDecember
2007”
Patient characteristics and set-
ting
Age: 62.8 +/- 18.3 years
Sex: approximately 2:1 ratio
SES: not reported
Ethnicity: Unclear
Stated Risk Factors: not reported
Number of patients/lesions: 135/182
Lesion site: Oral cavity
Severity: Quote “clinically diagnosed as squamous cell carcinoma (SCC) or suspicious epithelial
lesions”
Country: Germany
Type of facility: Secondary
Prevelance: 113/182
Index tests Category: Cytology - Cytobrush
Description:Quote “The cytologic sampleswere obtainedusing theCytobrush PlusGT.The brushes
were obtained from the lesions in a rotating manner without local anaesthetic so that petechial
bleeding points occurred in the majority of cases.”
Positivity threshold: Quote “subgroups of benign hyperplasia or hyperkeratosis, mild, moderate or
severe dysplasia, and SCC were used to classify the cytologic diagnoses”
Sequence of tests: Index followed by reference.
Training or calibration of clinicians: unclear
Blinding of examiners: Quote “All cytologic smears were examined blindly, i.e. without informa-
tion on the patient or the result of the histological examination, by an independent, experienced
cytopathologist”
Multiple tests: No
Method of site selection: Most suspicious region of the lesion was sampled.
Conflict of interests: Not reported.
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Scalpel, quote “Following the sampling for cytologic analysis, all oral lesions were
examined by taking a conventional biopsy by excision”
Positivity threshold: Two classification systems: SCC and carcinoma in situ; high risk lesions of SIN
II/III and SCC
Sequence of tests: Index followed by reference.
Training or calibration of pathologists: Unclear but two pathologists for each sample - 3 pathologists
in total
Blinding of examiners: Analysed by different specialists.
Multiple tests: No
Method of site selection: Most suspicious region of the lesion was sampled.
Target condition: Dysplasia and carcinoma.
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: same time
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote “78 patients participating in the study attended the outpatient
clinic of the Oral and Maxillofacial Surgery clinic of the Mainz University Medical Centre and
suffered from suspicious oral mucosal lesions”
Patient characteristics and set-
ting
Age: Mean 61.7
Sex: 59% male, 41% female
SES: not reported
Ethnicity: not reported
Stated Risk Factors: not reported
Number of patients/lesions: 78/78
Lesion site: Cheek 26, Gingival 22, Floor of the mouth 7, Sulcus glossoalv. 2, Tongue lower side 2,
Tongue dorsum 3, Palate 8, Arcus palatogloss. 5, Inner lips 3
Severity: 41% red, like erythroplakia (17%) or erythroleukoplakia (24%); 21% white, like leuko-
plakia
21% ulcerous; 17%, a speckled, including fibrin-covered lesions
Country: Germany
Type of facility: University Medical Centre
Prevalence: 33/78
Index tests Category: Light based
Description: Quote “Two different investigation methods were applied: the standard examination
by white light and the examination by a 400-nm wavelength light source that is supposed to trigger
a green light emission (>500 mm) in normal mucosa.” Documented by digital reflex photography
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Positivity threshold: SCC, and dysplasia [identified] depending on two different autofluorescence
features:
(1) A black or dark green aspect, as well as red indicating dysplasia or SCC (positive). Also, a
speckled, heterotopic aspect of both green and autofluorescence negative or reddish regions indicated
a positive finding
(2) The presence of red mucosal autofluorescence was evaluated as a separate indicator for dysplasia
or SCC (positive)
Sequence of tests: Index then reference
Training or calibration of clinicians: Not clearly discussed
Blinding of examiners: One experienced examiner performed the visual examination, two examiners
examined the photographs, they were blinded and independent
Multiple tests: Visual then light, class as one index test only, as an adjunct
Method of site selection: Not discussed
Conflict of interests: None
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: quote “a biopsy by incisionwas performed.Then, the biopsieswere fixedwith formalde-
hyde 4.5% and processed for light microscopy via paraffin-embedded, haematoxylin-eosin-stained
slices.”
Positivity threshold: Mucosal hyperkeratosis, Lichen planus, SCC, Inflammation, Dysplasia,
Healthy mucosa
Sequence of tests: Index then Reference
Training or calibration of pathologists: performed by one experienced examiner
Blinding of examiners: not described
Multiple tests: no
Method of site selection: biopsy of photographed lesion
Target condition: SCC and dysplasia
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Biopsy taken immediately after index test.
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes Results calculated from sensitivity and specificity in table 2
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
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Low
DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Study characteristics
Patient sampling Method of patient selection: Quote “Fifty-eight patients (mean age, 57.7 y; range, 34-74 y) with a
suspected squamous cell carcinoma of the oral cavity were investigated.”
Patient characteristics and set-
ting





Stated Risk Factors: Quote “All patients had a history of smoking and of drinking alcohol”
Number of patients/lesions: 58/160
Lesion site: oral cavity
Severity: not discussed
Country:Germany
Type of facility:not discussed
Prevalance: 100/160
Index tests Category: Light based
Name of test(s): Imaging 5-Aminolevulinic Acid-Induced Protoporphyrin IX Fluorescence
Description: Quote “5-Aminolevulinic acid....... was used in a 0.4% rinsing solution. The patients
performed a 15-minute continuous rinsing of the oral cavity using the 5-ALA solution. After an
incubation period of 1 to 2.5 hours, fluorescence investigation was performedwith the patient either
awake (n = 42) or under general anaesthesia during surgery (n = 16).”
Positivity threshold: strong, macroscopically visible red fluorescence (F++), weak (F+) or negative
(F−)
Sequence of tests: index then reference
Training or calibration of clinicians: unclear
Blinding of examiners: unclear
Multiple tests: unclear
Method of site selection: light-based detection
Conflict of interests: not discussed
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote “Biopsy specimens were taken from tumor, tumor boundaries, and normal
tissue under fluorescence illumination.”
Positivity threshold: Quote “histological diagnoses of squamous cell carcinoma, carcinoma in situ,
and severe and moderate dysplasia were classified as malignant, whereas light dysplasia and normal
tissue were classified as benign”
Sequence of tests: index then reference
Training or calibration of pathologists: not discussed
Blinding of examiners: not discussed
Multiple tests:no
Method of site selection: specimens taken from identified sites
Target condition: Quote “histological diagnoses of squamous cell carcinoma, carcinoma in situ, and
severe and moderate dysplasia were classified as malignant, whereas light dysplasia and normal tissue
were classified as benign.”
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Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Unclear




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote “A thorough examination of the oral soft tissue was conducted
formost patients if asymptomatic mucosal alterations were observed then patients were referred for
an evaluation, then rescheduled 10-14 days later for re-evaluation and TB testing.” Implied that the
14 day period is part of recruitment process and patients are not deemed part of the study if lesions
do not persist. Conditions recorded squamous cell carcinoma (invasive), carcinoma in situ, atypia,
or benign (hyperplasia, keratosis, inflammation, etc.)






Stated Risk Factors: Not reported
Number of patients/lesions: 178/235
Lesion site: Oral Cavity
Severity: asymptomatic mucosal alterations:
Country: US
Type of facility: Secondary - Veteran Administration Medical Centre so concern over wider appli-
cability
Prevalance: 105/235
Index tests Category: Vital staining - Toluidine Blue
Description: Photographed before and after direct application of stain, 2x mouth rinse with water
(20 secs each), 1 rinse with 1% acetic acid solution (20 secs), area dried with gauze, ’1% toluidine
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blue solution containing acetic acid and alcohol’ applied with cotton swab, rinse with acetic acid
solution (1 min), rinse with water
Positivity threshold: Quote “positive for malignancy if the lesion stains dark blue (royal or navy);
either the entire lesion or a portion of it may stain solidly or stippled . Occasional equivocal stains
are considered positive unless proven otherwise.”
Sequence of tests: TB then biopsy
Training or calibration of clinicians: not discussed, possibly only one examiner
Blinding of examiners: not explicitly stated but implied as biopsy results are returned for comparison
with TB results
Multiple tests: No
Method of site selection: Not described, assumed sites of lesions after examination
Conflict of interests: not reported
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: ’A biopsy of the stained areas was performed’ or ’a biopsy of the most suspicious area
as defined by our erythroplastic criteria was performed’
Positivity threshold: Invasive carcinoma or Carcinoma in situ
Sequence of tests: index then reference
Training or calibration of pathologists: not discussed
Blinding of examiners:not discussed
Multiple tests:no
Method of site selection: Quote “A biopsy of the stained areas was performed” or “a biopsy of the
most suspicious area as defined by our erythroplastic criteria was performed”
Target condition: Invasive carcinoma, Carcinoma in situ, Atypia, Benign
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: description implied biopsy taken immediately after rinsing
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes Re-analysed data to include atypia as positive (atypia defined in text as epithelial dysplasia),
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Test group A
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If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Study characteristics
Patient sampling Method of patient selection: Quote “Patients presenting to an oral medicine specialist unit for assess-
ment of an oral mucosal lesion were recruited into the study”,“The only criterion for inclusion was
referral for examination of an oral mucosal white lesion that was deemed to be clinically suspicious
and warranted further evaluation by routine measures including definitive histopathology”
Patient characteristics and set-
ting
Age: Mean age 56.6 (range 26-87.2)
Sex: 27 Female (mean age 57.06); 23 Male (mean age 56.03)
SES: Not reported
Ethnicity: Not reported
Stated Risk Factors: Smoking habits (20/50 - 40%) and regular alcohol consumption (26/50 - 52%)
; 18/50 (36%) were both tobacco and alcohol consumers
Number of patients/lesions: 50 patients/ 50 lesions
Lesion site: Tongue, buccal mucosa, floor of mouth, alveolar ridge, gingiva, palate, lip
Quote: “Location of primary and satellite lesions is listed in Table 2, with the majority of primary
lesions occurring on the tongue and buccal mucosa.”
Quote “Oral mucosal white lesions”
Severity: Clinically suspicious lesions, sufficient to be referred to an oral medicine specialist unit for
assessment.
Quote: “deemed to be clinically suspicious and warranted further evaluation by routine measures.”
Country: Queensland, Australia.
Type of facility: Secondary care, Oral medicine specialist unit
Prevalence: 9/50
Index tests Category: Light based - Microlux
Description: Visual examination, with dimmed operatory lights, examiner-worn LED white-head-
light, and handheld re-usable LED diffused white-light guide to illuminate irregular cells
Quote: “clinical examination was repeated using Microlux/DL diffused light illumination kit.”
“examinations were undertaken first without the 1% acetic acid solution and then repeated after
the recommended 60-s rinse procedure”
Positivity threshold: Quote: “After rinsing with the acetic acid solution, the manufacturer states that
irregular cells will take on a whitish hue which will contrast with the surrounding tissues making it
more obvious to the examiner” “Borders were designated either as diffuse or sharp.”
Sequence of tests: Index followed by reference
Training or calibration of clinicians: Not reported.
Blinding of examiners: Index completed prior to reference.
Multiple tests: Yes (light with/without acetic acid)
Method of site selection: Not reported
Conflict of interests: Quote: “The authors declare that they have no financial or personal relationship
with any party or product that could inappropriately influence or bias the results of this study.”
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote: “An incisional scalpel biopsy was performed under local anaesthesia to obtain
a definitive histopathological diagnosis which would serve as the gold standard. Biopsy specimens
were fixed in formalin, blocked in paraffin, stained with haematoxylin and eosin, and assessed by
routine histopathology by an experienced pathologist, not involved with the clinical study, using
recognised measures of interpretation.”
Positivity threshold: Quote: “A histopathological diagnosis of dysplasia was considered positive for
the presence of disease in these comparisons.”
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Sequence of tests: Index test followed by reference standard.
Training or calibration of pathologists: Unclear, however performed by experienced pathologist.
Blinding of examiners: Quote “not involved with the clinical study”
Multiple tests: No
Method of site selection: Not specifically reported; however, it is implied that the biopsy selection
site was intended to be the clinically suspicious lesion warranting further investigation, in addition
to any satellite lesions identified during the index test
Target condition: Dysplasia/OSCC.
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: reference performed immediately after index test
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes The analysis data for sensitivity and specificity is dysplasia/OSCC, taken from table 5
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Unclear
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
No
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote “Ninety-four patients with suspicious oral lesions fromDepart-
ments of Otorhinolaryngology and Pathology, Moti Lal Nehru Medical College, Allahabad, India,
were studied in a random manner”
Patient characteristics and set-
ting
Age: range 10 to 80
Sex: 76% male, 24% female
SES: not reported
Ethnicity: not reported, India
Stated Risk Factors: 54% tobacco consumption, 35% exposure to carcinogen, 5% heavy alcohol
use
Number of patients/legions: 94/94, 79 provided adequate brush biopsies
Lesion site: Oral cavity
Severity: ’Only lesions with an abnormal epithelial surface including erythroplakia, leukoplakia
without dysplasia and oral submucous fibrosis were included’
78Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mehrotra 2008 (Continued)
Country: India
Type of facility: Medical College
Prevalance: 34/79
Index tests Category: Cytology - baby toothbrush
Description: A hard nylon baby tooth brush, using moderate pressure, was repeatedly brushed in
one direction over the entire lesion until pinpoint bleeding was obtained. The material from the
brush was spread on to dried glass slides. The smears were fixed immediately with 100% ethanol
for staining with hematoxylin and eosin and the modified Papanicolaou’s method
Positivity threshold: Cells showing changes were categorised as malignant quote “enlarged nuclei,
variation in nuclear size and shape (pleomorphism), nuclear borders, nucleo:cytoplasmic ratio,
number of nuclei, binucleation, keratinization, tadpole forms, and hyperchromatism chromatin”
Sequence of tests: Index followed by reference
Training or calibration of clinicians: not discussed, quote “specimens were examined manually
independently by 2 different cytopathologists” not clear how experienced these cytopathologists
were
Blinding of examiners: quote “examined manually independently by 2 different cytopathologists in
a double blind fashion”, also blind to the reference analysis
Multiple tests: No
Method of site selection: Not reported
Conflict of interests: Not discussed
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: quote “For histological diagnosis (after routine processing and paraffin embedding),
several sections (3- to 4-m thickness) were cut from each case and stained with hematoxylin and
eosin.”
Positivity threshold: WHO criteria was used to classify into grade I to III
Sequence of tests: Index then reference
Training or calibration of pathologists: not described
Blinding of examiners: Quote “All specimens were examinedmanually, independently by 2 different
pathologists in a double-blind fashion.”
Multiple tests: No
Method of site selection:not reported, assumed taken from the site that received the brush biopsy
Target condition: dysplastic
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 15 samples were deemed inadequate for analysis
so did not receive ’full’ index test
Time interval: reference test biopsy immediately followed the index test




Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Patients selected for study after detection of a clinically innocuous
lesion (Class II) during routine dental care
Quote “PatientswithClass II lesions for subsequent evaluationwith the light-based adjunct screening
tools....We excluded patients with Class I lesions detected with a conventional overhead examination
light (and referred them for treatment) and those without any oral lesions.”
Patient characteristics and set-
ting
Age: mean age 40 years
Sex: 28 female, 230 male
SES: Not stated
Ethnicity: Not stated
Stated Risk Factors: Tobacco usage 70.5%
Number of patients/lesions: 258/258 split into two groups of 102 ViziLite+, 156 VELscope
Lesion site: Buccal mucosa, retromolar trigone, tongue, alveolar mucosa, gingiva, floor of mouth,
palate
Severity: Identified as Class II prior to biopsy, so patients classified as Class I (quote “suspicious
enough to warrant a biopsy”) were excluded
Country: India
Type of facility: Quote: “outpatient department of the government-run District Hospital ”
Prevalance: 12/156 & 4/102, combined 116/258
Index tests Index test 1 - VELScope
Category: Light-based
Description: Quote: “The clinicians performed the examinations with the VELscope and ViziLite
devices according to the manufacturers’ instructions”
Positivity threshold: Quote “Normal mucosa-a negative VELscope finding-appears as a bright green
glow, while abnormal mucosa-a positive VELscope finding-is identified by a loss of fluorescence and
appears dark.”
Sequence of tests: Quote “depending on which screening aid was available, underwent an examina-
tion with VELscope or ViziLite. The assignments were completely random” followed by reference
standard
Training or calibration of clinicians: Calibrated by an experienced professional from the manufac-
turer, no results reported
Blinding of examiners: Index test examiners blind to reference test results.
Multiple tests: Yes; conducted independently during the same session, by the same examiners
Method of site selection: Principle area ofmorphology decided by consensus after visual examination
Conflict of interests: Quote: “None of the authors reported any disclosures.”
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Index test 2 - Vizilite Plus
Category: Light-based
Description: Quote: ”The clinicians performed the examinations with the VELscope and ViziLite
devices according to the manufacturers’ instructions“
Positivity threshold: Quote: “a positive ViziLite finding-appeared aceto white. The ViziLite Plus
with TBlue system also contains a toluidine blue dye, which is intended to be used only to mark
lesions for follow-up examination that are positive according to the ViziLite screening.”
Sequence of tests: Quote ”depending on which screening aid was available, underwent an examina-
tion with VELscope or ViziLite. The assignments were completely random” followed by reference
standard
Training or calibration of clinicians: Calibrated by an experienced professional from the manufac-
turer, no results reported
Blinding of examiners: Index test examiners blind to reference test results.
Multiple tests: Yes; conducted independently during the same session, by the same examiners
Method of site selection: Principle area ofmorphology decided by consensus after visual examination
Conflict of interests: Quote: “None of the authors reported any disclosures.”
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote: “Using the standard scalpel technique”.
Positivity threshold: Not specifically stated.
Sequence of tests: Index test followed by reference standard.
Training or calibration of pathologists: Not reported, although results interpreted by two examiners
Blinding of examiners: Index test completed before reference standard. Quote “independently com-
paring pathological examination results with those obtained with these visual screening aids”
Multiple tests: Yes. COE; light-based detection adjunct (‘randomised’ to one of two); biopsy
Method of site selection: Not specifically reported.
Target condition: Quote: “potentially dysplastic and cancerous oral lesions”
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Assumed that reference test biopsy immediately followed the index test, but not
specifically stated
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes Velscope and Vizilite plus tests reported independently so data extracted for both
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
No
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Low
DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Mehrotra 2011
Study characteristics
Patient sampling Method of patient selection: Quote “Patients who were at least 18 years of age presenting with
unrelated complaints to the outpatient Department of Otorhinolaryngology , Moti Lal Nehru
Medical College inAllahabad,were screenedby a teamof specialist and residents-in-training between
July andNovember 2010. Patient with an oral epithelial abnormality that appeared clinically benign-
minimally suspicious - and did not have an obvious etiology such as trauma or infection were
prospectively enrolled.”
Patient characteristics and set-
ting
Age: mean 45.5, range 25 to 75 years
Sex: 55 male, 30 female
SES: not reported
Ethnicity: not reported, India
Stated Risk Factors: 37 (44%) tobacco use, 9 (11) alcohol use, both 10 (12%).
Number of patients/legions: 85/85, only 79 used in results, 6 samples were inadequate
Lesion site: Oral cavity
Severity: Quote “Patients with an oral epithelial abnormality that appeared clinically benign- min-
imally suspicious - and did not have an obvious etiology such as trauma or infection were prospec-
tively enrolled.”
Country: India
Type of facility: Medical College
Prevalance: 27/79
Index tests Category: Cytology
Description: Quote “A specially designed brush was used to obtain a transepithelial specimen from
all patients” samples were then “sent for further processing to OralCDx Laboratories® (Suffern,
New York, USA)”
Positivity threshold: Three categories: negative- no epithelial abnormality; atypical - abnormal ep-
ithelial changes; positive definitive evidence of epithelial dysplasia or carcinoma
Sequence of tests: Index followed by reference
Training or calibration of clinicians: Training yes but calibration unclear. Quote “Training of in-
vestigators consisted of providing verbal instructions and watching video for performing the oral
brush biopsy”
Blinding of examiners: Quote “results were determined in a blinded fashion, independent of the
scalpel biopsy”
Multiple tests: No
Method of site selection: Not reported
Conflict of interests: No competing interests
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote: “After the brush biopsy was performed, the same investigator performed a
scalpel biopsy of the lesion and in the same location tested with the brush biopsy”.
Positivity threshold: Not specifically stated.
Sequence of tests: Index test followed by reference standard.
Training or calibration of pathologists: unclear
Blinding of examiners: Index test completed before reference standard.
Multiple tests: no
Method of site selection: Not specifically reported but ’same part of the lesion sampled’
Target condition: Quote: ’dysplasia or carcinoma’.
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Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: reference test biopsy immediately followed the index test





Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote “Thirty consecutive patients with lesions suggestive of being
premalignant identified by a conventional clinical oral examination under incandescent light were
included into the study”
Patient characteristics and set-
ting
Age: 50.3 (SD, 15.7) years (range, 23-80 years).
Sex: 9 females and 21 males
SES: not discussed
Ethnicity: not discussed
Stated Risk Factors: 10 current cigarette smokers, 11 prior cigarette smokers; 2 regular consumers
of alcohol, 1 regular consumer of alcohol and tobacco
Number of patients/lesions: 30/41
Lesion site: not discussed
Severity: not discussed
Country: Poland
Type of facility: University Medical College
Prevalence: 7/41 dysplasia and SCC
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Index tests Category: Vital staining plus adjunct - Vizilite Plus
Description: Initial visual examination, then 1% acetic acid rinse followed by evaluation under
chemiluminescent light. Lesions then swabbed with 1% acetic acid, followed by application of
toluidine blue and a further swab of acetic acid, and a visual examination under incandescent light
to asses toluidine blue retention
Positivity threshold: Quote “chemiluminescence examination including the brightness, sharp-ness,
surface texture, and size of the lesion using a 4-point scale (decreased, no change, slight improvement,
marked improvement)” “tolonium chloride examination including the staining pattern using a 3-
point scale (negative, incomplete, complete)”.Not clear which level of coloration equates to negative,
incomplete or positive
Sequence of tests: Index then reference
Training or calibration of clinicians: not discussed
Blinding of examiners: not discussed
Multiple tests: one combined test. Data taken from combined results in Table 4
Method of site selection: visual and chemiluminescent examination
Conflict of interests: none stated
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote “incisional biopsy under local anaesthesia, and sample tissues on which biopsy
was performed were submitted for histopathologic assessment”
Positivity threshold: Positive result: Dysplasia, SCC; Negative: Benign keratosis, Lichen planus,
Normal oral mucosa
Sequence of tests: index then reference
Training or calibration of pathologists: not described
Blinding of examiners: not described
Multiple tests: no
Method of site selection: visual examination of index test
Target condition: dysplasia or squamous cell carcinoma
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: not reported
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes Table 4 used for data
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Low
DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Unclear
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Study characteristics
Patient sampling Method of patient selection:
Quote “The study group consisted of 60 subjects of both the sexes, 30 subjects with clinically
suspicious premalignant lesions and30 subjectswith clinically suspiciousmalignant lesions.’ Subjects
who fulfilled the following criteria were selected for the study: leukoplakia, speckled leukoplakia,
erosive lichen planus, oral malignancy.”
Quote: “A provisional diagnosis of leukoplakia, speckled leukoplakia, erosive lichen planus (prema-
lignant lesions) and oral malignancies were made on basis of clinical examination.”





Ethnicity: not reported (India)
Risk Factors: not stated
Number of patients/lesions: 30/30 with clinically suspicious premalignant lesions and 30/30 with
clinically suspicious malignant lesions
Lesion site: oral cavity
Severity: premalignant lesions (degree of dysplasia), malignant lesions (degree of differentiation)
Country: India
Type of facility: Department of Oral Medicine and Radiology, Bapuji Dental College and Hospital,
Davangere, Karnataka
Prevalence: 55/60
Index tests Category: Vital staining - Toluidine-Blue combined with Lugol’s iodine
Description: Quote “The subjects comfortably seated in the dental chair were examined following
the methods described by Kerr et al.”
Positivity threshold: Either or both of the tests staining positive.
Toluidine Blue: Quote “Dark blue stain was considered as positive for lesions suspicious of malig-
nancy, light blue retention was considered as positive for premalignant lesions unless proved other-
wise by biopsy and the lesions without any retention of stain were considered as negative”
Lugol: Quote: ’Interpretation of the Lugol’s iodine stain Brown stain was considered as positive for
lesions while lesions without any retention of stain were considered as negative.’
Sequence of tests: TB Staining followed by Lugol’s iodine followed by reference standard
Training or calibration of clinicians: No training reported
Blinding of examiners: Index test completed before reference standard.
Multiple tests: No but a combination of 2 tests.
Method of site selection: quote “Biopsy site was selected on the basis of clinical appearance and dye
retention and in the sites where no retention of the stain occurred, clinical judgment directed the
biopsy”
Conflict of interests: Not stated
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote: “Histopathological grading for premalignant lesions was performed as per the
pathologic features suggested by Axell et al.”
Positivity threshold: Quote “grouped on the basis of degree of dysplasia into those with no dysplasia,
mild dysplasia, moderate dysplasia and severe dysplasia. Oral malignancies were graded into well-
differentiated (Grade I), moderately differentiated (Grade II) and poorly differentiated (Grade III)
squamous cell carcinoma (SCC).”
Sequence of tests: Index test followed by reference standard
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Training or calibration of pathologists: Not stated
Blinding of examiners: not reported
Multiple tests: no
Method of site selection: Quote “Biopsy site was selected on the basis of clinical appearance and
dye retention and in the sites where no retention of the stain occurred, clinical judgment directed
the biopsy.”
Target condition: Oral cancer and precancer (dysplasia)
Flow and timing Patients receiving index tests but not reference test: 0
Patients receiving reference test but not index tests: 0
Time interval: Biopsy based on dye retention assume within acceptable interval




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
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Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: patients with lesions clinically identified as suspicious for carcinoma
or dysplasia
Patient characteristics and set-
ting
Age: 68.9 (14.33)
Sex: 49% female 51% male
SES: not reported
Ethnicity: white
Risk Factors: not stated
Number of patients/lesions: 78/78
Lesion site: not reported
Severity: not clear
Country: Italy
Type of facility: Oral Pathology service of University Hospital
Prevalence: 45/78
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Index tests Category: Cytology - Cytobrush
Description: The first 14 cases cytobrush was employed, for the other cases a wooden spatula. The
lesion was scraped with the instrument, avoiding bleeding. cells were spread on a glass slide, fixed
and stained by Papanicolaou method
Positivity threshold: not reported
Sequence of tests: not reported
Training or calibration of clinicians: not reported
Blinding of examiners: not reported
Multiple tests: No
Method of site selection: not reported
Conflict of interests: not reported
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: The same day of cytology, one or more samples were taken after vital staining of the
lesion with toluidine blue
Positivity threshold:not reported
Sequence of tests: not reported
Training or calibration of pathologists: not reported
Blinding of examiners:not reported
Multiple tests: some cases underwent multiple biopsy
Method of site selection: toluidine blue
Target condition: dysplasia and carcinoma
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Same day.




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
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If a threshold was used, was it
pre-specified?
Unclear
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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Study characteristics
Patient sampling Method of patient selection: Quote “Patients with oral PMLs, referred to the OralMedicine Section
of the University of Turin, Italy entered this study. Patients with clinical features suggestive of
carcinoma were not excluded.”






Stated Risk Factors: not reported
Number of patients/legions: 164/164 six micro-biopsies did not provide adequate specimens
Lesion site: Oral cavity
Severity: PMLs
Country: Italy
Type of facility: Oral Medicine Section of the University Hospital
Prevalance: 73/158
Index tests Category: Cytology - Curette
Description: Quote “Patients first underwent a scraping from the whole surface of the oral lesion
to be examined and care was taken to cause slight bleeding, so as to ensure that the basal layers of
the epithelium had been sampled. This sampling was carried out using a disposable dermatological
curette (Acu-Dispo Curette, Acuderm Inc., Ft. Lauderdale, FL, USA) and the material was placed
into the Thin Prep (Cytic Corporation, Marlborough, MA, USA) vial.”
Positivity threshold: Dysplasia, carcinoma or negative, quote “The diagnosis of dysplasia or carci-
noma was based on recognized WHO criteria. The diagnosis was recorded as either negative or
positive for the presence of neoplasia or dysplasia, whatever the grade”
Sequence of tests: Curette immediately followed by scalpel, both slides assessed simultaneously
Training or calibration of clinicians: Three pathologists participating in the study to avoid inter-
examiner and intra-examiner, training/calibration not discussed
Blinding of examiners: No, quote “micro-biopsy and scalpel biopsy histological slides were assessed
simultaneously by the same pathologists”
Multiple tests: No
Method of site selection: not reported
Conflict of interests: Quote “This study has been supported in part by MURST ex-60%Universita‘
di Torino’, Ricerca Finalizzata Regione Piemonte’ and by a grant of Compagnia di San Paolo -
Programma Oncologia’, Torino, Italy.”
Target condition and reference
standard(s)
Category: Scalpel biopsy with histopathologic assessment
Description: Quote “Immediately after the curette sampling, scalpel biopsies were performed ac-
cording to the following procedure. Local anaesthesia was used, taking care not to infiltrate the lesion
itself to avoid artefacts; then one or more representative samples with a diameter of at least 6 mm
were taken, focusing on ulcerated, red or verrucous areas where present together with a surrounding
area of normal tissue, using either a scalpel or a punch.”
Positivity threshold:quote “The diagnosis of dysplasia or carcinoma was based on recognizedWHO
criteria”
Sequence of tests: Index then reference for cell collection, analysis conducted simultaneously
Training or calibration of pathologists: not described
Blinding of examiners: not blinded
Multiple tests: No
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Method of site selection:not reported
Target condition: PMLs - dysplasia and carcinoma
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 6 samples from curette biopsy deemed inadequate,
quote “The micro-biopsies were defined adequate when a representative (at least 100 not superficial
cells) strip of epitheliumwas present, whilst, when only hornymaterial (anucleated cells) was present,
they were defined as inadequate.”
Time interval: Reference test biopsy immediately followed the index test
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes Concern over use of: quote “The small tissue fragments present in the Thin Prep vial were placed
into buffered formalin, to be processed histologically as micro-biopsies”, while the remaining cytol-
ogy specimen was stored up to be used for other investigations (not reported in this study)
Contradiction between results tables and data in text. Data used for analysis from table 2 which
agrees to sensitivity and specificity presented in results
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
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out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote: “retrospective chart review of a consecutive selection of patients
who had both a biopsy and a concurrent QC assessment from 2008 to 2010”
Patient characteristics and set-
ting
Age: median age 58 years
Sex: 82 male 89 female
SES: not reported
Ethnicity: not reported
Stated Risk Factors: 87 smokers 84 non-smokers
Number of patients/legions: 171
Lesion site: Oral mucosa
Severity: PMDs and OSCC
Country: British Columbia, Canada
Type of facility: community referral-based oral medicine clinic
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Prevalance: 28/171
Index tests Category: Cytology - Oral Advance
Description: QC samples were collected using the Oral Advance kit, using a flexible cytology brush.
Image analysis followed by visual cytomorphologic analysis
Positivity threshold: High-grade epithelial dysplasia and SCC Quote: “A QC-positive finding is
rendered when there is presence of DNA content abnormality confirmed with the cytopathologist’s
visual interpretation.” High risk PMD and SCC
Sequence of tests: Index followed by reference.
Training or calibration of clinicians: Quote; “Visual assessment of nuclear abnormality was per-
formed according to the guidelines pertained to nuclear morphology, namely the presence of
anisonucleosis and nuclear pleomorphism.” No information on calibration reported
Blinding of examiners: Quote: “mucosal biopsy specimens were obtained from the same lesions and
sent to 2 different pathology laboratories for independent evaluation in a blinded fashion.”
Multiple tests: No
Method of site selection: Quote: “multiple locations of the suspicious lesion 10 times in one direc-
tion.”
Conflict of interests: One of the authors is a general pathology consultant at Perceptronix Medical,
the company offering the Oral Advance index test
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Surgical biopsy “Oral biopsies were then taken from the same lesion in a conventional
surgical fashion.”
Positivity threshold: Quote “The histopathologic diagnosis was classified into 4 groups according
to the presence and the degree of epithelial dysplasia, as summarized in Table II: benign, low-risk
PMD, high-risk PMD, and SCC”
Sequence of tests: Index then reference.
Training or calibration of pathologists: Not discussed.
Blinding of examiners: Yes “Nonaffiliated hospital based (Oral Biopsy Service, Vancouver, BC,
Canada) oral and maxillofacial pathologists carried out tissue pathologic interpretation per World
Health Organization guidelines.” and “The oral pathologists were blinded from any QC-related
information.”
Multiple tests: No
Method of site selection: Oral biopsy taken from the same site as exfoliative cytology
Target condition: Severe dysplasias and carcinoma in situ.
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Reference test biopsy immediately followed the index test quote “concurrent QC
assessment”
Patients receiving both index and reference test but excluded from analysis: 28 cases were selected
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Yes
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Participants had been referred for examination and treatment of oral
lesions to Division of Oral and Maxillofacial Surgery, University Hospital of Tsukuba Hospital,
Japan
Patient characteristics and set-
ting
Age: mean 60 range 23-92 years
Sex: 77 men 53 women
SES: not reported
Ethnicity: Japanese
Stated Risk Factors: not reported
Number of patients/legions: 130
Lesion site: Oral cavity
Severity: unclear
Country: Japan
Type of facility: Secondary
Prevalance: 86/130
Index tests Category: Light based
Description: Fluorescence photography with ultraviolet flash.
Positivity Threshold: Quote “The autofluorescence of the lesions was judged according to the
intensity of fluorescence depicted in the film. Final judgement was subject to agreement by two or
more examiners.”
Sequence of tests: Index followed by reference
Training or calibration of clinicians: unclear
Blinding of examiners: Index completed prior to reference.
Multiple tests: No
Method of site selection: unclear
Conflict of interests: Not reported.
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Biopsy method unclear.
Positivity threshold: unclear
Sequence of tests: index followed by reference
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Training or calibration of pathologists: unclear
Blinding of examiners: index was conducted independent of reference test.
Multiple tests: not applicable
Method of site selection: unclear
Target condition: Carcinoma and dysplasia
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: not discussed
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes Data extractable for oral cancer as target condition
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Unclear
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Unclear
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Unclear





Patient sampling Method of patient selection: Quote “Fifty patients with PMELs and superficial oral ulcerations
suggestive of malignancy were selected from those treated at the Oral Medicine Service, Faculty of
Dentistry, Araraquara, Brazil from August 1993 to May 1995 (n = 1957)”
Quote “Not included in this study were patients who refused to be submitted to biopsy (n = 21),
those who abandoned treatment, or those who had clinically obvious invasive carcinomas or lesions
without risk or suspicion of malignancy.”
Patient characteristics and set-
ting
Age: mean age 55.2 years, SD 13.4 years
Sex: 22 females 28 males
SES: not reported
Ethnicity: 45 white, 2 black, 2 mixed race, 1 Asian
StatedRisk Factors: 34/50 smokers, 13/50 regular alcohol drinkers, 13 occupational regular exposure
to the sun
Number of patients/legions: 50/50
Lesion site: oral cavity
Severity: Quote: “PMELs and superficial oral ulcerations suggestive of malignancy”
Country: Brazil
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Onofre 2001 (Continued)
Type of facility: Quote “hospital based sample”
Prevalance: 13/50
Index tests Category: Vital staining - Toluidine blue
Description:Quote: “All lesionswere submitted to stainingwith an aqueous solutionof 1% toluidine
blue, ..” Followed recommendations of Mashberg (Mashberg 1980).
Positivity threshold: Followed recommendations of Mashberg (Mashberg 1980, Mashberg, 1983)
1) “inadequate cell count” 2) “negative” 3) “atypical epithelial cells” 4) “positive for dysplasia or
OSCC”
Atypical and positive results recorded as positive; inadequate results excluded
Sequence of tests: Index test followed by reference standard.
Training or calibration of clinicians: Quote “The clinical diagnosis and staining results were deter-
mined by 2 examiners, previously calibrated, who were specialists in oral medicine.“
Blinding of examiners: Not explicitly reported but index test was performed prior to reference
standard
Multiple tests: No
Method of site selection: Quote: “sites were selected on the basis of the clinical appearance of the
lesion and the staining result”
Conflict of interests: Quote “We are indebted to the Mario A.S. Paino Laboratory of Clinical
Pathology.”
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: biopsy and histologic analysis
Positivity threshold: any grade of dysplasia (in OL and OLP) and OSCC
Sequence of tests: Index test preceded reference standard.
Training or calibration of pathologists: Quote: “Previously calibrated pathologist.”
Blinding of examiners: Quote: ”pathologist was not informed of the staining result.”
Multiple tests: no
Method of site selection: Quote “The biopsy sites were selected on the basis of the clinical appearance
of the lesion and the staining result. Areas retaining stain were biopsied. In sites where no retention
of stain occurred, clinical judgment directed the biopsy.”
Target condition: Squamous cell carcinomas, Epithelial dysplasia, Keratosis, Lichen Planus
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: not reported
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes Clinical interpretation of cutoff required.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
102Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Onofre 2001 (Continued)
Was a consecutive or random
sample of patients enrolled?
No




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Pamphlets were issued inviting people to a self-examination 3 day
event, 849 attended, 158 had red and white lesions, only 86 consented
Patient characteristics and set-
ting
Age: mean 43 years (12.53)
Sex: 20.93% female 79.07% male
SES: not reported
Ethnicity: not reported
Stated Risk Factors: Tobacco usage 86.05%, Alcohol usage 40.69%. Both tobacco and alcohol
usage 59.3%
Number of patients/lesions: 86
Lesion site: not reported
Severity: quote “suspected of having oral premalignant lesions or oral squamous cell carcinoma”
Country: India
Type of facility: quote “3 day screening camp”
Prevalence: 27/86
Index tests Index Test 1 - Toluidine blue
Category: Vital staining
Description: ThemodifiedMashberg technique was used to prepare the 1% toluidine blue solution.
Following a rinse of water and 1% acetic acid solution, the toluidine blue solution was swabbed, a
further rinse with acetic acid solution was applied
Positivity threshold: a royal navy blue colour was considered positive, light blue not specified to be
positive or negative
Sequence of tests: toluidine blue, cytobrush, scalpel
Training or calibration of clinicians: not discussed
Blinding of examiners: not discussed
Multiple tests: Yes
Method of site selection: visual examination
Conflict of interests: not discussed
Index Test 2 - Cytobrush
Category: Cytology (following toluidine blue)
Description:Quote “Visually identified lesionswere then scrapedusing a cytobrush” “smears were….
.fixed in 95% alcohol or air dried and stained with hermatoxylin-eosin, Pap and PAS stains”
Positivity threshold: Footnote table 7, negative = Class I & II, atypical = Class III, IV & V
Sequence of tests: Toluidine blue, cytobrush, scalpel.
Training or calibration of clinicians: not discussed
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Blinding of examiners: All specimens were examined by two pathologists in a double blind fashion,
any discrepancies were resolved by a third opinion
Multiple tests: Yes
Method of site selection: Visual and staining
Conflict of interests: Not discussed
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment.
Description: The lesions were then biopsied using either scalpel or punch technique under local
anaesthesia
Positivity threshold: mild dysplasia classed as negative; moderate and severe classed as positive
Sequence of tests: Index then reference
Training or calibration of pathologists: Not discussed
Blinding of examiners: Blind to toluidine blue, but not visual examination, unclear regarding brush
biopsy
Multiple tests: No
Method of site selection: Visual examination
Target condition: SCC, CIS, dysplasia
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: All completed during the same appointment.
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes Study is a direct comparison of two independent tests, Toluidine blue and cytology, to be used
independently. Results reported as separate index tests with potential for incorporation bias with
index test of cytology
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Unclear
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Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Remmerbach 2009
Study characteristics
Patient sampling Method of patient selection: 47 patients referred for examination and treatment of oral lesions were
examined by an expert fromDept of Oral andMaxillofacial Surgery, University of Leipzig. Potential
selection of patients quote “After a thorough intraoral examination”
Patient characteristics and set-
ting




Stated Risk Factors: not reported
Number of patients/legions: 47
Lesion site: Oral cavity
Severity: referred for treatment of oral lesion
Country: Germany
Type of facility: Secondary
Prevalance: 20/47
Index tests Category: Cytology
Description: After an examination 4 smears were taken with a brush-based cell collector, rolled
on a glass slide and fixed with propanol. A series of different stains were applied: Papanicolaou
and Feulgen Staining, DNA Measurements performed, then AgNOR Analysis. All tracked with
Multimodal Cell Analysis
Positivity threshold:
’1) “insufficient” for specimens without any or with exclusively autolytic cells;
2) “tumor cell negative” for unsuspicious, reactive, or inflammatory cellular images;
3) “atypical” in cases with atypical cellular changes (e.g., with mild or moderate dysplasia);
4) “suspicious for tumor cells” if only sparse abnormal or severe dysplastic squamous cells were
observed or if the diagnostic criteria for malignancy were only vague; and
5) “tumor cell positive” for smears that contained unequivocal malignant cells’
(1) & (2) classified as negative
(3) - (5) positive
Sequence of tests: Index then reference test
Training or calibration of clinicians:Not discussed, patients examined by one person only who is
described as experienced
Blinding of examiners:Only one examiner, not discussed whether blind of histology
Multiple tests:Yes: Cytology, DNA, AgNOR
Method of site selection: According to examination
Conflict of interests:No conflict ’project is supported by the Viktor and Mirka Pollak Fund for
Biomedical Engineering and the Innovation Fund of the University Hospital Leipzig’
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment.
Description: Scalpel biopsy-based histology, which was validated by clinical follow-up
Positivity threshold: Squamous cell carcinomas considered positive. Negative results - leukoplakias,
lichen planus
Sequence of tests: Index then reference test.
Training or calibration of pathologists: Not discussed
Blinding of examiners: Not discussed
Multiple tests: No
107Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Remmerbach 2009 (Continued)
Method of site selection: Not described
Target condition: Squamous cell carcinomas
Flow and timing Patients receiving index test but not reference test: none
Patients receiving reference test but not index test: none
Time interval: assumed reference test biopsy immediately followed the index test
Patients receiving both index and reference test but excluded from analysis: none
Comparative
Notes Assuming independence between the three index tests.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
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Remmerbach 2009 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote “Oral and VELscope examinations were performed on 64
patients referred to the Department of Oral and Craniomaxillo-facial Surgery to rule out invasive
squamous cell carcinoma.” “Patients with advanced squamous cell carcinomas were excluded”
Twenty patients with previous history raise concern that examiners are already aware of patients
diagnosis
Patient characteristics and set-
ting
Age: average age of 59.8 years
Sex: 25 female and 39 male
SES: not discussed
Ethnicity: not discussed
Stated Risk Factors: not discussed
Number of patients/lesions: 64
Lesion site: Floor of mouth, Palate, Alveolar process, Tongue, Buccal mucosa
Severity: Patients with advanced SCC were excluded
Country: Germany
Type of facility: Department of Oral and Craniomaxillo-facial Surgery
Prevalence: 12/64
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Scheer 2011 (Continued)
Index tests Category: Light based - VELscope
Description: Quote “For evaluation of the suspicious lesions, the room was shaded and the hand
piece was covered with a lens cover.” “Through the back of the hand piece, tissue autofluorescence
above 480 nm could be identified as green light” and photographs be taken to record the outcome
Positivity threshold: Quote “the complete loss of the normal tissue fluorescence (fluorescence visu-
alization loss [FVL]) was rated as malignant or dysplastic alteration Red or orange fluorescence was
not considered as malignant”
Sequence of tests: Index then reference
Training or calibration of clinicians: Not reported although pictures were rated by an oral and
maxillofacial surgeon who had experience with this equipment since August 2007
Blinding of examiners: Quote “one experienced oral and maxillofacial surgeon without the knowl-
edge of the histologic result rated all examinations”
Multiple tests: No
Method of site selection: Not reported
Conflict of interests: None reported
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment.
Description: Quote ” All lesions underwent histopathological evaluation by a trained pathologist”
Positivity threshold:
positive results: SIN, SCC
Sequence of tests: Index then reference
Training or calibration of pathologists: Quote “All lesions under-went histopathological evaluation
by a trained pathologist after examination with the VELscope”
Blinding of examiners: Not discussed
Multiple tests: No
Method of site selection: Quote “Biopsies were taken from the area of fluorescence loss”
Target condition: SIN and Carcinoma.
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test:0
Time interval: Quote “All lesions under-went histopathological evaluation by a trained pathologist
after examination with the VELscope”




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Patient sampling Method of patient selection: Quote: ”80 consecutive patients between July 2002 and September
2003’. Inclusion criteria: “(1) an OralCDx brush biopsy of a lesion with the clinical diagnosis oral
leukoplakia (OL), oral lichen planus (OLP), or obvious oral squamous cell carcinoma (OSCC); and
(2) a scalpel biopsy that had been performed within one month before or after the brush biopsy of
the same lesion.”
Only those that received a scalpel biopsy were included in the study, not full spectrum of disease
leading to potential sampling bias
Patient characteristics and set-
ting
Age: mean age 58.6 years, SD 13.1 years,
Sex: 33 females 47 males
SES: not reported
Ethnicity: not reported
Stated Risk Factors: not reported
Number of patients/lesions: 80 / 96
Lesion site: Oral cavity
Severity: Oral CDx brush biopsy of a lesion with the clinical diagnosis of OL, OLP or OSCC.
Included patients at high level of severity only
Country: Germany
Type of facility: Quote: “hospital based sample”
Prevalance: Dysplasia or carcinoma 26/96 (lesion level)
Index tests Category: Cytology - Oral CDx
Description: Quote “Brush biopsies were taken according to instructions and sent to the Oral CDx
centre in Germany.”
Positivity threshold: Based on previous study (Sciubba 1999)
Quote “1) “inadequate cell count”, 2) “negative”, 3) “atypical epithelial cells”, 4) “positive for
dysplasia or OSCC””
Quote: “Atypical and positive results recorded as positive; inadequate results excluded.”
Sequence of tests: Quote “scalpel biopsy that had been performed within one month before or after
the brush biopsy of the same lesion”
Training or calibration of clinicians: Not reported
Blinding of examiners: Not reported
Multiple tests: No
Method of site selection: Not reported. Quote “according to instructions”
Conflict of interests: Quote “OralCDx test kits and Oral CDx analyses for this study were provided
by the German Oral CDx centre, …, Germany.”
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Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment.
Description: Scalpel biopsy-based histology.
Positivity threshold: Any grade of dysplasia (in OL and OLP) and OSCC.
Sequence of tests: Quote “scalpel biopsy that had been performed within one month before or after
the brush biopsy of the same lesion”
Training or calibration of pathologists: Not reported
Blinding of examiners: Not reported
Multiple tests: No
Method of site selection: Not reported
Target condition: Dysplasia and squamous cell carcinomas
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: One month
Patients receiving both index and reference test but excluded from analysis: 7/103 Quote: “Overall,




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Yes
Was calibration of examin-
ers undertaken and results re-
ported?
Unclear
113Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Scheifele 2004 (Continued)
Wheremultiple index testswere
used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote “Suspicious lesions (categorized as Class I) were analysed by
use of both OralCDx and scalpel biopsy. Apparently innocuous lesions (categorized as Class II)
that, in the investigators’ opinion, required no further attention other than clinical follow-up were
tested only by use of OralCDx. Patients with apparently innocuous lesions that produced abnormal
OralCDx results, as defined below, subsequently were subjected to scalpel biopsy at the investigators’
discretion.”
Patient characteristics and set-
ting
Age: mean 55 range 18-83
Sex: male 443 (47%), female 502 (53%)
SES: not reported
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Sciubba 1999 (Continued)
Ethnicity: not reported
Stated Risk Factors: Cigarette use, Other Tobacco, Alcohol.
Number of patients/legions: 945/945 in total study, 298/298 ’suspicious lesions’ received both index
and reference
Lesion site: oral cavity, includes Oropharynx
Severity: Quote “intraoral lesions displaying an epithelial componen”’ then classified into suspicious
and innocuous
Country: US
Type of facility: Dentists specialising in oral and maxillofacial pathology, oral medicine and oral
surgery obtained the specimens in the course of their routine clinical practice
Prevalance: 102/298
Note: although selecting those with a ’suspicious lesion’ this is still an acceptable population
Index tests Category: Cytology - Oral CDx
Description: Quote “the flat surface or circular border of the brush was placed against the surface
of the lesion and, while firm pressure was maintained, rotated five to 10 times. Pinkness of tissue or
pinpoint bleeding at the brush biopsy site was evidence of proper technique.” “material collected
on the brush then was transferred to the bar-coded glass slide and rapidly flooded with the fixative
to avoid airdrying.” “All OralCDx specimens were analyzed at OralScan Laboratories in Suffern,
N.Y.”
Positivity threshold: negative: no epithelial abnormality; atypical: abnormal epithelial changes of
uncertain diagnostic significance; positive: definitive cellular evidence of epithelial dysplasia or
carcinoma; inadequate: incomplete transepithelial biopsy specimens (these specimens were excluded
from the study)
Sequence of tests: Index then reference (assumed)
Training or calibration of clinicians: Quote “The great majority of investigators had been trained
in the oral brush biopsy and slide preparation technique at an investigators meeting, and all were
provided with written instructions.”
Blinding of examiners: Quote “The pathologist analysing the OralCDx specimen was masked from
all of the clinical and demographic data as well as histologic results”
Multiple tests: No
Method of site selection: Not specified.
Conflict of interests: Funded by OralScan Laboratories Inc. who produce OralCDx products
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment.
Description: Quote “oral and maxillofacial pathologists at the investigators dental institutions his-
tologically evaluated all scalpel biopsy specimens.”
Positivity threshold: Results reports as Malignant or Dysplastic, Benign or Not Performed
Sequence of tests: Index then reference test.
Training or calibration of pathologists: Not discussed
Blinding of examiners: Not discussed
Multiple tests: No
Method of site selection: Not described
Target condition: Malignant or Dysplastic
Flow and timing Patients receiving index test but not reference test: Class 1 cases 0, but class 2 cases 618
Patients receiving reference test but not index test: 0
Time interval: Assumed reference test biopsy immediately followed the index test
Patients receiving both index and reference test but excluded from analysis: 0
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Comparative
Notes All class 1 received both index and reference test, class 2 received index then reference - if positive
to index. Can only look at results of class 1
In data, classified Positive & Atypical as a positive result
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Yes
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote “samples obtained through OralCDx ® on 24 patients who
visited the Master of Oral Medicine, Oral Surgery and Implantology of the University of Santiago
de Copmostela, referred by the SERGAS (Servizo Galego de Saúde - Galician Public Healthcare
System), between February 2009 and May 2010 who showed clinical and histological lesions that
were consistent with oral leukoplakia in different clinical forms.”
Patient characteristics and set-
ting
Age: mean 62.38 (12.14 SD)
Sex: 12 male 12 female
SES: Not stated
Ethnicity: Not stated
Stated Risk Factors: Not stated
Number of patients/legions: 24/24
Lesion site: oral cavity
Severity: Quote: “showed clinical and histological lesions that were consistent with oral leukoplakia
in different clinical forms.”
Country: Spain
Type of facility: secondary care facility
Prevalance: 11/24
Index tests Category: Brush cytology - OralCDx
Description: Quote “brush sampling by performing 10 to 20 lateral or frontal rotations, in a
representative area (never on an ulcer) until the area turns reddish or a light dotted hemorrhage; we
then transferred the sample on to the pre-coded slide, placing the fixative to avoid contamination
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Seijas-Naya 2012 (Continued)
of the sample.”
Positivity threshold: Positive for presence of dysplasia or carcinoma. All categories are atypical
(cellular changes of uncertain diagnosis), positive for dysplasia or carcinoma, negative (normal cells)
and inappropriate (incomplete transepithelial sample)
Sequence of tests: Index followed by reference
Training or calibration of clinicians: No details stated for training or calibration.
Blinding of examiners: Not stated
Multiple tests: No
Method of site selection: Not stated
Conflict of interests: Not stated
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Surgical biopsy
Positivity threshold: Negative - no epithelial alteration, positive - dysplasia
Sequence of tests: Index followed by reference
Training or calibration of pathologists: Not stated
Blinding of examiners: Not stated
Multiple tests: No
Method of site selection: Not stated
Target condition: Dysplasia
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Quote: “All patients had a sample taken with a surgical scalpel 3 weeks prior or after
sampling with the OralCDx ® kit to compare our results.”




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Unclear
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Seijas-Naya 2012 (Continued)
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
Yes
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Sharwani 2006a
Study characteristics
Patient sampling Method of patient selection:Quote: “Seventy-one patients with clinically suspicious oral leukoplakia
took part in this study”
Patient characteristics and set-
ting




Stated Risk Factors: Not reported
Number of patients/legions: 71/71 only 69 reported in results
Lesion site: Oral cavity
Severity: Quote: “clinically suspicious oral leukoplakia”
Country: UK
Type of facility: Quote: “Maxillofacial Unit, University College Hospital (UCH) London.”
Prevalence: 31/69
Index tests Category: Light based - 5 ALA
Description: Quote: “Three hours prior to examination, topical application to the oral mucosa
was performed via a rinsing solution of 0.4% 5-ALA hydrochloride;” “Following examination, the
images produced (Fig. 1) were analysed by the computer to identify the area of the highest signal.”
Positivity threshold: Given in Figure 2. The ratio (red/green) was set at 1.2 or 1.3 as the threshold
demarcation between normal and dysplastic. Unclear if this was decided prior to the study see 2.2
Sequence of tests: Index followed by reference standard.
Training or calibration of clinicians: Unclear
Blinding of examiners: Unclear
Multiple tests: No
Method of site selection: Not reported
Conflict of interests: Not reported
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote: “surgical biopsies were taken from various oral sites, where the majority orig-
inated from the tongue, buccal mucosa and floor of the mouth. These biopsies were examined
histopathologically and were found to be either normal (normal, inflammatory or hyperkeratotic)
or potentially malignant (mild, moderate or severe dysplastic).”
Positivity threshold: Results report as normal or potentially malignant (see above)
Sequence of tests: Index followed by reference test.
Training or calibration of pathologists: Not reported.
Blinding of examiners: Not reported.
Multiple tests: No.
Method of site selection: Quote: “Each of the patients was required to have 5-aminolevulinic acid in
the form of mouth rinse prior to fluorescence imaging. Following this a surgical biopsy was acquired
from the exact examination site.”
Target condition: Malignant or Dysplastic
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Assumed reference test biopsy immediately followed the index test
Patients receiving both index and reference test but excluded from analysis: Two
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Comparative
Notes Badly reported. Used 1.2 threshold for results.
1.3 level results: TP 26, FN 5, TN 34, FP 4.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Unclear
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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of the results of the index tests?
Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote: “Twenty-five patients, 13 males and 12 females, (mean age 52
years, range 41-67 years) with clinically suspicious oral leukoplakia took part”
Patient characteristics and set-
ting
Age: Mean age 52 years, range 41- 67
Sex: 13 M, 12 F
SES: Not reported
Ethnicity: Not reported
Stated Risk Factors: Not reported
Number of patients/legions: 25/25
Lesion site: Oral cavity
Severity: Quote: “Clinically suspicious oral lesions”
Country: UK
Type of facility: Quote: “..Maxillofacial Unit, University College Hospital (UCH) London.”
Prevalence: 11/25
Index tests Category: Light based - Elastic Scattering Spectroscopy (ESS)
Description: Quote: “The ESS system [...] is a prototype that was designed and built at the Los
Alamos National Laboratory, USA. The system consists of a pulsed xenon-arc lamp for the light
source, a PC-compatible spectrometer, which employs a linear charged coupled device (CCD) array
for detection, an optical fibre (graded-index) based probe, and a laptop computer for system control
and data display.”
“Three optical measurements were acquired from each of the suspected lesions; 1st measurement
from the centre, 2nd from the periphery of the lesion and in between the two measurements the
3rd was acquired.”
Positivity threshold: Quote: “In this clinical trial, all types of dysplasia were classified as ‘malignant’
whereas all other reports (normal, inflammation, and hyperkeratosis) were considered ‘non-malig-
nant or benign’ changes.”
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Sequence of tests: Index followed by reference standard.
Training or calibration of clinicians: Not reported.
Blinding of examiners: Not reported
Multiple tests: No
Method of site selection: Not specifically reported.
Conflict of interests: Quote: “We are grateful to ”The British Association of Oral and Maxillofacial
Surgeons“ who provided the funding for this study.”
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote “25 biopsies were taken from various oral sites, and examined histopathologi-
cally.”
Positivity threshold: Quote “In this clinical trial, all types of dysplasia were classified as ’malignant’
whereas all other reports (normal, inflammation, and hyperkeratosis) were considered ’non-malig-
nant or benign’ changes.”
Sequence of tests: Index followed by reference.
Quote: “ESS was used to examine the suspicious area of each of those patients prior to surgical
biopsy.”
Quote: “Following the optical readings, a surgical biopsy was taken.”
Training or calibration of pathologists: Training not reported; however, report indicates implied
experience of pathologist due to precise description of process undertaken
Blinding of examiners: Not reported
Multiple tests: No
Method of site selection: Not specifically reported, but indicated.
Quote: “ESS was used to examine the suspicious area of each of those patients prior to surgical
biopsy.”
Quote: “The 25 biopsies were taken from various oral sites, and examined histopathologically.”
Target condition: Malignant (including dysplasia) or carcinoma in situ
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Text implies reference test biopsy immediately followed the index test. Quote: “Fol-
lowing the optical readings, a surgical biopsy was taken”
Patients receiving both index and reference test but excluded from analysis: Ten
Comparative
Notes Unclear why 10 histologically confirmed hyperkeratotic lesions were excluded from the analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
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Low
DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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Study characteristics
Patient sampling Method of patient selection: Quote “The study group comprised 132 consecutive patients seen in
the oral medicine clinic who were suspected of having oral carcinomas or precancerous (dysplastic)
lesions”






Stated Risk Factors: Not reported
Number of patients/lesions: 132/132
Lesion site: oral cavity
Severity: Quote “suspected of having oral carcinomas or precancerous (dysplastic) lesions”
Country: US
Type of facility: secondary oral medicine clinic
Prevalance: 99/132 (42 dysplastic and 57 carcinoma)
Index tests Category: Vital staining - Toluidine blue
Description:Quote “For staining, a 1%aqueous toluidine blue dye was applied for approximately 30
seconds, followed by a tap water rinse, and then lightly blotted with 1% acetic acid. Both solutions
were applied with cotton tipped applicators. Any dye uptake was recorded by photographs.”
Positivity threshold: Quote “If there was dye uptake, the biopsy specimen was taken from that area;
otherwise, clinical judgment guided the biopsy site.”
Sequence of tests: Toluidine blue followed by biopsy
Training or calibration of clinicians: Unclear
Blinding of examiners: Yes. Inferred although not stated.
Multiple tests: No
Method of site selection: Quote “If there was dye uptake, the biopsy specimen was taken from that
area; otherwise, clinical judgment guided the biopsy site.”
Conflict of interests: Not stated
Target condition and reference
standard(s)
Category: Biopsy
Description: Quote “The biopsy specimens were fixed in 10% neutral buffered formalin and sent
to the oral pathology laboratory for routine processing.”
Positivity threshold: Categorised as: Benign, dysplasia, carcinoma
Sequence of tests: Toluidine blue followed by biopsy
Training or calibration of pathologists: Not stated
Blinding of examiners: Not stated
Multiple tests: No
Method of site selection: Quote “If there was dye uptake, the biopsy specimen was taken from that
area; otherwise, clinical judgment guided the biopsy site.”
Target condition: Quote “oral lesions suspected of being precancerous or malignant”
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Simultaneous biopsy
Patients receiving both index and reference test but excluded from analysis:0
125Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Silverman 1984 (Continued)
Comparative
Notes Dysplasia and carcinoma extracted as positive for histology
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Unclear
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: 298 patients submitted for a scalpel biopsy that were known to have
also received a brush biopsy which proved to be abnormal
Patient characteristics and set-
ting
Age: mean 52 years, range 18-89
Sex: 51% women 49% men
SES: Not specified
Ethnicity: Not specified
Stated Risk Factors: Not specified
Number of patients/legions: 298
Lesion site: Ventral/lateral tongue 90; Palate 63; Gingiva 65; Buccal/Alveolar mucosa 43; Floor of
mouth 8, unspecified/other 29
Severity: patients receiving a brush biopsy
Country: US
Type of facility: Pathology laboratories
Prevalance: 93/298
Index tests Category: Cytology - Oral CDx
Description: Brush biopsy with computer assisted method of analysis (Oral cdx)
Positivity threshold: Thresholds unclear.
Sequence of tests: Index then reference.
Training or calibration of clinicians: Not discussed
Blinding of examiners: Not discussed
Multiple tests: No
Method of site selection: Not clarified, but discussion around differing results due to brush and
scalpel taking sample from different parts of lesion
Conflict of interests: stated no conflict of interests, declaration of some funding from Oral CDx,
but involvement of Oral CDx labs is stated for retrospective analysis
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Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment.
Description: Biopsy process not described.
Positivity threshold: Dysplasia or carcinoma.
Sequence of tests: Index then reference
Training or calibration of pathologists: Not discussed, based on data from existing patients rather
than allocated specifically for the study
Blinding of examiners: Not discussed
Multiple tests: No
Method of site selection: Not explicitly reported
Target condition: Dysplasia or carcinoma.
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Not discussed
Patients receiving both index and reference test but excluded from analysis: Unclear
Comparative
Notes Lack of reporting on specifics of the methods undertaken for brush and scalpel biopsies, also the
patient recruitment, timing, blinding, calibration and number of assessors. Suspect this is because
the study tracks those patients with a scalpel biopsy and traces them back to the index test, so the
author would not know how the brush biopsy was undertaken
Assuming that there was a visual examination prior to the brush biopsy
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Unclear
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Yes
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Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote “Consecutive outpatients who visited the study centre and who
clinically presented with at least one precancerous lesion were recruited into this study”
Frank malignancy, hypersensitivity to ingredients in the light examination and any systemic disease
were all excluded
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Patient characteristics and set-
ting
Age: 44.4 (17.1)
Sex: Female 4, Male 51
SES: not discussed
Ethnicity: not discussed
Stated Risk Factors: Tobacco users (29%), tobacco and lime (60%), snuff (3.6%), betel nut (63.
6%) and alcohol (20%)
Number of patients/lesions: 55/99
Lesion site: Tongue, Palate, Buccal mucosa, Buccal vestibule, Commensural Mucosa, Retromolar
area, Labial vestibule
Severity: Lesions other than class I (clinically diagnosed)
Country: India
Type of facility: Oral Diagnosis, Medicine and Radiology Department of the Sharad Pawar Dental
College
Prevalence: 17/99
Index tests Category: Vital Staining plus light - Vizilite plus (reported separately)
Description: Quote “combination of chemiluminescence and toluidine blue (stain) retention test”
Positivity threshold: Quote “we considered a lesion to be CHTB-positive if it was both CHEM-
positive and TBLU-positive; otherwise the lesion was considered to be CHTB-negative”
CHBT = combined chemiluminescence and toluidine blue
CHEM = chemiluminescence only
TBLU = toluidine blue only
Sequence of tests: Chemiluminescence, then toluidine blue, then reference test
Training or calibration of clinicians: Not reported
Blinding of examiners: Not reported
Multiple tests: No, class as one index test.
Method of site selection: Conventional visual examination then chemiluminescence and staining
Conflict of interests: No
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment.
Description: Quote “collected in 10% formalin solution and processed”
Positivity threshold: Dysplasia (moderate and severe) or carcinoma classified as positive
Sequence of tests: Index then reference
Training or calibration of pathologists: Not discussed.
Blinding of examiners: Quote “Histopathologic evaluation was done by two senior Oral Pathologists
blinded to the clinical findings”
Multiple tests: No
Method of site selection: Not reported.
Target condition: No dysplasia, mild dysplasia, moderate dysplasia and severe dysplasia
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: All conducted in one session
Patients receiving both index and reference test but excluded from analysis: Unclear
Comparative
Notes Performed at lesion level
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote “47 patients visiting the Dental clinics of Manipal College of
Dental Sciences, Manipal, under routine OPD”
Exclusion of severe cases, those included are: quote “homogeneous Leukoplakia, speckled Leuko-
plakia, Erythroplakia & Erosive lichen planus”, not a representative spectrum of cases
Patient characteristics and set-
ting
Age: mean 53.83, range 31-75
Sex: 10 female, 37 male
SES: not discussed
Ethnicity: not discussed
Stated Risk Factors: not discussed
Number of patients/lesions: 47
Lesion site: not discussed
Severity: Quote “Clinically a provisional diagnosis of homogeneous Leukoplakia, speckled Leuko-
plakia, Erythroplakia & Erosive lichen planus”
Country: India
Type of facility: College of dental science
Prevalence: 27/47
Index tests Category: Vital staining - Toluidine blue
Description: Oral examination, water rinse for 20 sec, 1% acetic acid for 20 sec, rinse 5ml of 1%
toluidine blue, rinse 1% acetic acid 20 sec, water rinse
Positivity threshold:UsedMashberg levels, quote “doubtful light blue stainwas considered as positive
until biopsy proves the contrary”
Sequence of tests: Index then reference
Training or calibration of clinicians: Not discussed
Blinding of examiners: Not discussed
Multiple tests: No
Method of site selection: Visual examination
Conflict of interests: No conflict
Target condition and reference
standard(s)
Category: Biopsy with histopathologic examination
Description: Quote “A suitable incisional/punch biopsy was obtained on the basis of site retaining
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the stain” “Biopsy was also obtained from those lesions which did not retain any stain but were
clinically suggestive of a PMOL’s”
Positivity threshold: Quote “histologically categorized as (a) Benign: hyperkeratosis, hyperplasia, &
other non-malignant lesions, (b) Dysplasia: mild, moderate & severe dysplasia; and finally (c) Oral
squamous cell carcinoma (OSCC)”
Sequence of tests: index then reference
Training or calibration of pathologists: not discussed
Blinding of examiners: Quote “reviewed by two oral pathologists blinded to toluidine blue staining
results”
Multiple tests: no
Method of site selection: Based on toluidine blue staining
Target condition: See positivity threshold above.
Flow and timing Patients receiving index test but not reference test: 0
Patients receiving reference test but not index test: 0
Time interval: Not reported, implied to be taken during the same appointment
Patients receiving both index and reference test but excluded from analysis: 0
Comparative
Notes Included the OCSS results in the data table
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Yes
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
No
Was calibration of examin-
ers undertaken and results re-
ported?
Unclear
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Wheremultiple index testswere
used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Method of patient selection: Quote “The study was conducted in August 1993 in 7 centres in
Asia among a population of Sri Lankan and Pakistani subjects who consented to participate in the
programme. The consultant dental surgeon in each centre approved the appropriateness of each
included case.”
Quote “All patients had been referred to, or had attended, the specialist centres with unconfirmed
oral mucosal lesions.”
Patient characteristics and set-
ting
Age: mean age 60 SD 15 years
Sex: 73 men; 29 women
SES: not reported
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Ethnicity: Sri Lankan and Pakistani
Stated Risk Factors:
84 regular betel quid chewers (49 used tobacco in quid mixture)
28 tobacco smokers
4 Niswar users.
13 “known to misuse alcohol”
Quote “None had previously received regular dental care.”
Number of patients/lesions: 102/145 only 86 received index and reference test
Lesion site: oral
Severity: Invasive and dysplastic lesions (cf benign keratoses)
Country: 7 centres in Asia
Type of facility: secondary care (implied)
Prevalance: 57/86 lesions
Index tests Category: Vital staining - Toluidine blue
Description:Quote “The rinse protocol usingOraScan [1%toluidine blue]was as permanufacturer’s
instructions ... except that the study was limited to a single TB rinse per person and not repeated
14 days later.”
Positivity threshold: Results classed as positive or negative (including equivocal) but no thresholds
reported. The equivocal lesions were excluded
Sequence of tests: Staining followed by reference standard
Training or calibration of clinicians: No training reported
Blinding of examiners: Index test completed before reference standard
Multiple tests: No
Method of site selection: TB rinse - No site selection
Conflict of interests: KASSW supported by Dunhill Medical Trust. Consumables in project funded
by Zila Pharmaceuticals
Target condition and reference
standard(s)
Category: Biopsy with histopathologic assessment
Description: Quote “Tissues were bisected so that one portion of the biopsy could be fixed in
buffered formal saline and the other in 10% alcohol; specimens were then transported to London,
Following processing in wax, 6-jim sections were cut at two levels and stained with H&E and PAS,
Microscopy diagnosis and, where relevant, degree of dysplasia were recorded independently by two
experienced histopathologists blinded to the dye results”
Positivity threshold: Quote “Dysplasias were graded as mild, moderate or severe, using the intensity
of the signs specified by SMITH & PiNDBORG, When there was disagreement, concordance was
reached following consultation.”
Sequence of tests: Index test followed by reference standard
Training or calibration of pathologists: Not stated, but experienced histopathologist.
Blinding of examiners: quote “blinded to the dye results”
Multiple tests: No
Method of site selection: ’Sites stained by the dye were charted and re-photographed. 86 clinically
detected lesions, dye-retained or not, were biopsied. Ten patients had two biopsies taken from
separate areas of their lesions corresponding to the dye result, one from a stain-positive area and
another from a stain-negative site.’
Target condition: Oral cancer and dysplasia.
Flow and timing Patients receiving index tests but not reference test: patient data not given, of 145 lesions 86 (or 87
in abstract) received biopsy, 59. Not reported how biopsies were selected
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Patients receiving reference test but not index tests: 0
Time interval: Biopsy consecutive to staining





Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear




DOMAIN 2: Index Test Test group A
If a threshold was used, was it
pre-specified?
Unclear
Were there any conflicts of in-
terest? (if no information given
at all then judge as unclear)
Yes
Was calibration of examin-




used were the results of the sec-
ond index test interpreted with-
out knowledge of the first index
test?
Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes




CIS: carcinoma in situ
OLP: oral lichen planus
COE: conventional oral examination
H&E: haematoxylin and eosin
OSCC: oral squamous cell carcinoma
PMD: potentially malignant disorders
PMELs: potentially malignant epithelial lesions
TB: toluidine blue
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Betz 2002 Inappropriate patient selection, quote “85 patients with a histologically proven malignancy”. For inclusion
the index test is to be performed on patients presenting with clinically evident lesion, who are not already
diagnosed
Bhoopathi 2009 Only reports on those with positive or atypical brush biopsy
Burkhardt 2010 Letter linked to Hohlwel-Majert.
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Driemel 2007 Unsure of patient sampling to obtain brush biopsies or when the biopsies were undertaken. The index test
and reference standard were not performed at the same time
Driemel 2007b Unsure of patient sampling to obtain brush biopsies or when the biopsies were undertaken
Driemel 2008 Inappropriate classification of inadequate samples.
Ebenezar 2012 Inapropriate population.
Epstein 1995 Reference test not a scalpel biopsy.
Gomez Serrano 1989 Not all patients received both index and reference test.
Hedge 2006 Not all presenting with oral lesions, quote ’oral lesions or mucosal alterations suspicious of malignancy’
Hohlwleg-Majert 2009 75 investigated, 6 excluded: 1 number of cells inadequate, 1 topographical error biopsy, 3 no histology. See
critical comments by Burkhardt 2010 querying histology and results. Results cannot been extracted
Jayaprakash 2009 Data compromised by the inclusion of normal/control lesions.
Kulapaditharon 1998 Insufficient data.
Lane 2012 Data unavailable for true positive, true negative, false positive, false positive. Author contacted but no reply
Levine 1998 Unclear how patients were selected or clinical pathway.
Li 2004 All patients recently diagnosed with oral cancer.
Majumder 2006 Patients had no clinically evident lesions.
Mallia 2010b Patients had no clinically evident lesions.
Maraki 2004 Cannot obtain satisfactory data to calculate sensitivity and specificity
Maraki 2006 Cannot obtain satisfactory data to calculate sensitivity and specificity
Navone 2007 Presentation of ’inadequate’ cells make the calculation of sensitivity and specificity impossible from the
data provided
Navone 2009 Data not presented to allow interpretation of sensitivity/specificity
Nieman 2008 Difficulties in clarifying the date, no response from contact author
Poate 2004 60 of the 75 who has a negative brush biopsy result did not have an incisional biopsy as the reference
standard
Rana 2012 Reference test only performed on positive index test results
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Reboires-Lopez 2012 No reference test.
Remmerbach 2001 Reported on number of samples (smears) taken, not at patient level
Remmerbach 2003 Case control study.
Remmerbach 2004 Quote “1328 exfoliative smears of 332 different lesionswere comparedwith histology and/or clinical follow-
ups”, reported at smear/lesion level not patient
Remmerbach 2007 Reported on number of samples (smears) taken, not at patient level, same numbers of patients and lesions
as 2004 study
Sandler 1964 Diagnosis of cytology was used to determine whether biopsy would be undertaken
Schwarz 2009 66 patients without suspected oral lesions were included.
Shklar 1970 DTA study on a highly selected group. Selection criteria was histological diagnosis of epidermoid carcinoma
Silverman 1992 Re-publication of 1984 study.
Swider 1984 No data for sensitivity or specificity.
Torres-Rendon 2009 Takes an archive of samples rather than using the adjunctive test in the secondary care setting
Wang 2009 No data for sensitivity or specificity- also uses 40 normal controls
DTA = Diagnostic Test Accuracy
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Presented below are all the data for all of the tests entered into the review.






1 Vital staining 15 1338
2 Cytology 12 1575
3 Light-based 11 988
4 Vital staining plus adjunct
(Light)
4 339
5 Vital staining plus adjunct
(Cytology)
2 139
Test 1. Vital staining.
Review: Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions
Test: 1 Vital staining
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Allegra 2009 26 1 4 14 0.87 [ 0.69, 0.96 ] 0.93 [ 0.68, 1.00 ]
Awan 2012 23 22 18 29 0.56 [ 0.40, 0.72 ] 0.57 [ 0.42, 0.71 ]
Cancela-Rodriguez 2011 19 35 10 96 0.66 [ 0.46, 0.82 ] 0.73 [ 0.65, 0.81 ]
Chen 2007 26 9 3 20 0.90 [ 0.73, 0.98 ] 0.69 [ 0.49, 0.85 ]
Cheng 2003a 16 2 9 3 0.64 [ 0.43, 0.82 ] 0.60 [ 0.15, 0.95 ]
Cheng 2003b 24 1 5 0 0.83 [ 0.64, 0.94 ] 0.0 [ 0.0, 0.97 ]
Du 2007 31 25 2 70 0.94 [ 0.80, 0.99 ] 0.74 [ 0.64, 0.82 ]
Mashberg 1980 101 8 16 110 0.86 [ 0.79, 0.92 ] 0.93 [ 0.87, 0.97 ]
Nagaraju 2010 55 4 0 1 1.00 [ 0.94, 1.00 ] 0.20 [ 0.01, 0.72 ]
Onofre 2001 10 13 3 24 0.77 [ 0.46, 0.95 ] 0.65 [ 0.47, 0.80 ]
Rahman 2012 18 11 9 48 0.67 [ 0.46, 0.83 ] 0.81 [ 0.69, 0.90 ]
Silverman 1984 97 10 2 23 0.98 [ 0.93, 1.00 ] 0.70 [ 0.51, 0.84 ]
Ujaoney 2012 10 17 7 65 0.59 [ 0.33, 0.82 ] 0.79 [ 0.69, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
(Continued . . . )
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Upadhyay 2011 21 14 6 6 0.78 [ 0.58, 0.91 ] 0.30 [ 0.12, 0.54 ]
Warnakulasuriya 1996 47 11 10 18 0.82 [ 0.70, 0.91 ] 0.62 [ 0.42, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. Cytology.
Review: Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions
Test: 2 Cytology
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Delavarian 2010 16 0 2 8 0.89 [ 0.65, 0.99 ] 1.00 [ 0.63, 1.00 ]
Koch 2011a 108 4 7 63 0.94 [ 0.88, 0.98 ] 0.94 [ 0.85, 0.98 ]
Mehrotra 2008 30 3 4 42 0.88 [ 0.73, 0.97 ] 0.93 [ 0.82, 0.99 ]
Mehrotra 2011 26 5 1 47 0.96 [ 0.81, 1.00 ] 0.90 [ 0.79, 0.97 ]
Navone 2004 39 2 6 31 0.87 [ 0.73, 0.95 ] 0.94 [ 0.80, 0.99 ]
Navone 2008 71 12 2 73 0.97 [ 0.90, 1.00 ] 0.86 [ 0.77, 0.92 ]
Ng 2012 27 3 45 96 0.38 [ 0.26, 0.50 ] 0.97 [ 0.91, 0.99 ]
Rahman 2012 19 13 8 46 0.70 [ 0.50, 0.86 ] 0.78 [ 0.65, 0.88 ]
Scheifele 2004 24 4 2 66 0.92 [ 0.75, 0.99 ] 0.94 [ 0.86, 0.98 ]
Sciubba 1999 102 14 0 182 1.00 [ 0.96, 1.00 ] 0.93 [ 0.88, 0.96 ]
Seijas-Naya 2012 8 1 3 12 0.73 [ 0.39, 0.94 ] 0.92 [ 0.64, 1.00 ]
Svirsky 2002 93 150 4 51 0.96 [ 0.90, 0.99 ] 0.25 [ 0.20, 0.32 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. Light-based.
Review: Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions
Test: 3 Light-based
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Farah 2007 10 45 0 0 1.00 [ 0.69, 1.00 ] 0.0 [ 0.0, 0.08 ]
Farah 2012 11 29 15 63 0.42 [ 0.23, 0.63 ] 0.68 [ 0.58, 0.78 ]
Koch 2011b 31 1 2 44 0.94 [ 0.80, 0.99 ] 0.98 [ 0.88, 1.00 ]
Leunig 2000 97 22 3 38 0.97 [ 0.91, 0.99 ] 0.63 [ 0.50, 0.75 ]
McIntosh 2009 7 12 2 29 0.78 [ 0.40, 0.97 ] 0.71 [ 0.54, 0.84 ]
Mehrotra 2010 6 88 6 56 0.50 [ 0.21, 0.79 ] 0.39 [ 0.31, 0.47 ]
Onizawa 1999 75 2 5 42 0.94 [ 0.86, 0.98 ] 0.95 [ 0.85, 0.99 ]
Scheer 2011 12 10 0 42 1.00 [ 0.74, 1.00 ] 0.81 [ 0.67, 0.90 ]
Sharwani 2006a 28 8 3 30 0.90 [ 0.74, 0.98 ] 0.79 [ 0.63, 0.90 ]
Sharwani 2006b 8 1 3 3 0.73 [ 0.39, 0.94 ] 0.75 [ 0.19, 0.99 ]
Ujaoney 2012 17 81 0 1 1.00 [ 0.80, 1.00 ] 0.01 [ 0.00, 0.07 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Vital staining plus adjunct (Light).
Review: Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions
Test: 4 Vital staining plus adjunct (Light)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Epstein 2008 42 15 0 40 1.00 [ 0.92, 1.00 ] 0.73 [ 0.59, 0.84 ]
Mehrotra 2010 0 24 4 74 0.0 [ 0.0, 0.60 ] 0.76 [ 0.66, 0.84 ]
Mojsa 2012 7 25 0 9 1.00 [ 0.59, 1.00 ] 0.26 [ 0.13, 0.44 ]
Ujaoney 2012 10 17 7 65 0.59 [ 0.33, 0.82 ] 0.79 [ 0.69, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. Vital staining plus adjunct (Cytology).
Review: Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions
Test: 5 Vital staining plus adjunct (Cytology)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guneri 2011 14 22 1 6 0.93 [ 0.68, 1.00 ] 0.21 [ 0.08, 0.41 ]
Gupta 2007 44 3 2 47 0.96 [ 0.85, 0.99 ] 0.94 [ 0.83, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Index tests for oral cancer and PMDs
Test Characteristics Classification of response Other information
Conventional oral examination
(COE)
A standard visual and tactile
examination of the oral mu-
cosa under normal (incandes-
cent) light
The presence of an oralmucosal
abnormality with a suspicion of
malignancy or potential malig-
nancy is classified as a positive
test result; the presence of oral
mucosal abnormality without a
suspicion of malignancy or po-
tential malignancy is classified
as a negative test result
Traditionally used as a oral can-
cer screen rather than diagnosis,
but its utility is debated (Lingen
2008).
Advantages: quick and easy
once trained, minimally inva-
sive.
Disadvantages: oral mucosal
abnormalities are not necessar-
ily clinically or biologically ma-
lignant; only a small percent-
age of leukoplakias are pro-
gressive or become malignant,
COE cannot distinguish be-
tween those that are or are
not; some precancerous lesions
may exist within oral mucosa
that appears clinically normal
by COE alone (Lingen 2008).
Vital staining (e.g. toluidine
blue, tolonium chloride)
Vital staining refers to the use
of dyes such as toluidine blue or
tolonium chloride to stain oral
mucosa tissues for PMD orma-
lignancy (Leston 2010; Lingen
2008; Patton 2008). The pro-
cedure is as follows:
The result of the test is classified
as positive if tissue is stained and
negative if no tissue is stained,
or equivocal if no definitive re-
sult can be obtained
Advantages: ability to define
areas that could bemalignant or
abnormal but cannot be seen;
assess the extent of the PMDfor
excision
Disadvantages: benign inflam-
matory lesions are subject to
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Table 1. Index tests for oral cancer and PMDs (Continued)
• Pre-rinse with acetic acid
• Rinse with water
• Apply toluidine blue
• Post rinse with acetic acid
• Rinse with water
• Observe mucosa to check
for staining
stain; possibility of failure of
some cancerous lesions to stain;
possibility of failure of some
dysplastic lesions (particularly
those with a lower grade or
with a thick keratotic surface)
to stain; variation in test perfor-
mance depending on how thor-
ough the test procedures are fol-
lowed; contraindicated in those
who are known to be allergic to
iodine
Brush cytology (e.g. OralCDx
brush biopsy)
Brush cytology refers to the mi-
croscopic assessment and in-
terpretation of cell samples
from PMD that are flaked off
from the oral mucosa by the
brushing, smearing, scraping or
lavage to collect cell samples,
which are then sealed on glass
slides. They are then analysed
using an imaging system that as-
sesses the sampled cells (Leston
2010; Lingen 2008; Patton
2008).
Following analysis, cytopathol-
ogists classify test results as pos-
itive, atypical or negative
Advantages: include the abil-
ity to collect information from,
and detect large or multiple le-
sions and to access “the base-
mentmembrane collecting cells
from all three epithelial layers
of the oral mucosa. The liq-
uid-based cytology reduces the
problems relating to sampling
and fixation and presents a bet-
ter cytological morphology” (
Divani 2009).
Disadvantages: smaller or less
obvious lesions may be over-
looked; difficulties in detecting
lesions when there is necrosis or
coagulated blood; inadequate
training of operators (Divani




g. ViziLite plus, tissue fluores-
cence imaging e.g. ViziLite,Mi-
crolux DL; VELscope, Identafi
3000; tissue fluorescence spec-
troscopy)
Light-based systems to identify
malignant and potentially ma-
lignant lesions and to highlight
their presence through tissue re-
flectance (Leston 2010; Lingen
2008; Patton 2008) e.g. using
Microlux DL, the procedure is
as follows (Lingen 2008).
• Pre-rinse with acetic acid
• Use blue-light source to
visually assess the oral cavity.
ViziLlite Plus also provides
a tolonium chloride solution
(toluidine blue) to aid in the
marking of the lesion for biopsy
The result of the test is classed
as negative if the appearance of
the epithelium is lightly bluish
white and positive if the appear-
ance of the epithelium is dis-
tinctly white (acetowhite)
Advantages: simple to use;
non-invasive; do not require
consumable reagents; provide
real-time results; can be per-
formed by a wide range of op-
erators after a short training pe-
riod
Disadvantages: the necessity of
a dark environment; high ini-
tial set up (for VELscope) or
recurrent costs (for ViziLite in
low-income countries); lack of
permanent record unless pho-
tographed; inability to objec-
tively measure visualisation re-
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Table 1. Index tests for oral cancer and PMDs (Continued)
once the light source is removed sults
Blood and saliva analysis These novel technologies are
at an early stage of develop-
ment and evaluation. Analy-
sis of blood or saliva samples
which tests for the presence of
biomarkers of PMD and oral
cancer (Brinkmann 2011; Lee
2009; Li 2006).
Cut-off probabilities
vary widely and are dependent
on the individual biomarker or
combination of biomarkers ex-
amined
Advantages: non-invasive
(saliva tests) or minimally inva-
sive (blood tests)
Disadvantages: there is a ten-
dency for the estimated diag-
nostic accuracy of new health
technologies to decline over
time as evidence from inde-
pendent evaluations accumu-
late (Wyatt 1995). This bias,
which can be substantial, has
been demonstrated in other do-
mains, e.g. acute abdominal
pain (Liu 2006) and clinical
decision support systems (Garg
2005). Promising biomarker
tests in several clinical areas
were eventually been shown
to be disappointing (Buchen
2011). It remains to be seen
whether this is the case with oral
cancer and PMDs
COE = conventional oral examination; PMD = potentially malignant disorders
Table 2. Indicators for the assessment of quality (QUADAS-2)
Domain Patient selection Index test Reference standard Flow and timing






of the target condition
(class), intended use of
index test and setting).
Describe the index test
(s) and how it was con-
ducted and interpreted.
Describe the sequence of
tests, any training or cali-
bration of clinicians (lev-
els of agreement should
be reported; where this is
measured by the kappa
statistic, acceptable val-
ues
range from 0.61 (mod-
erate agreement) to 1.
00 (almost perfect agree-
ment) (Landis 1977)),
any procedures taken to
Describe the reference
standard and how it was
conducted and inter-
preted. Ideally, the biop-
sied tissue should be ex-
amined by more than
one pathologist. If there
is a lack of agreement
any methods for reach-
ing consensus should be
clearly documented. Any
measures taken to en-
sure pathologists were
blinded to the results of
the index tests should be
documented, along with
Describe the character-
istics and proportion of
patients who did not
receive the index test
(s) and/or reference stan-
dard, who received a
reference standard other
than the scalpel biopsy,
or who were excluded
from the 2 x 2 table
(refer to flow diagram)
. Describe the time in-
terval and any interven-
tions between index test
(s) and reference stan-
dard. The length of time
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Table 2. Indicators for the assessment of quality (QUADAS-2) (Continued)
ensure blinding of exam-
iners, post-hoc or a priori
threshold specification,
any conflict of interest
or commercial funding.
Methods of site selection
should be clearly docu-
mented
the sequence of reference
and index tests.Methods
of site selection should
be clearly documented
between the index test
and reference standard
should be short in the
majority of cases. If the
period elapsed between
index test and reference
standard is greater than





Was a consecutive or ran-
dom sample of patients
enrolled?
Classify as ’Yes’ if consec-
utive patients or a ran-
dom sample of individu-
als were recruited
Classify as ’No’ if non-
consecutive patients or
a non-random sample
of individuals were re-
cruited
Classify as ’Unclear’ if
patient selection was not
clearly described.
Was calibration of exam-
iners undertaken and re-
sults reported?




to an acceptable standard
Classify as ’No’ if the ex-
aminers did not partici-
pate in dedicated train-
ing or was not assessed,
or training was under-
taken but calibrationwas
not to an acceptable
standard
Classify as
’Unclear’ if the informa-
tion on training and cal-
ibration was not stated
Is the reference standard
likely to correctly classify
the target condition?
Clas-
sify as ’Yes’ if the biopsy
was independently con-
firmed by at least two
qualified pathologists
Classify as ’No’ if the
biopsy was not inde-
pendently confirmed by
at least two qualified
pathologists, or therewas
lack of agreement be-
tween pathologists
Classify
as ’Unclear’ if the study
does not state who con-
firmed the biopsy.
Was there an appropri-
ate time interval between
the index test(s) and ref-
erence standard?
Classify as ’Yes’ if the
delay between the in-




Classify as ’No’ if the
delay between the in-
dex test(s) and reference
standard is considered
unacceptable for the ma-
jority of participants
Classify as ’Unclear’ if
the delay between the in-
dex test(s) and reference
standard is not explicitly
stated
Did the study avoid in-
appropriate exclusions?
Classify as ’Yes’ if pa-
tients with either class I
or class II lesions were re-
cruited
Classify as ’No’ if only
patients with class I le-
sions were recruited.
Classify as ’Unclear’ if
class of lesions was not
clearly described.
Were the index test re-
sults interpreted without
knowledge of the results
of the reference stan-
dard?
Classify as ’Yes’ if in-
terpreters of index test
results clearly do not
know results of biopsy/
histopathology
Classify as ’No’ if inter-
preters of index test re-




Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?
Classify as ’Yes’ if pathol-
ogists clearly do not
know the index test re-
sults when interpreting
biopsied tissues
Classify as ’No’ if pathol-
ogists know the results of
index test results when
interpreting biopsied tis-
sues
Classify as ’Unclear’ if
Did all patients receive
the same reference stan-
dard?
Classify as ’Yes’ if the
same reference standard
was used in all partici-
pants
Classify as ’No’ if the
same reference standard
was not used in all par-
ticipants
Classify as ’Unclear’ if it
is unclear whether differ-
ent reference standards
were used
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Table 2. Indicators for the assessment of quality (QUADAS-2) (Continued)
as ’Unclear’ if study did
not provide any infor-
mation on whether in-
terpreters of index tests
were blinded to biopsy/
histopathology
the study did not pro-
vide any information on
whether the pathologists
were blinded to the index
test results
Where multiple index
tests were used, were the
results of the second in-
dex test interpretedwith-
out knowledge of the re-
sults of the first index
test?
Classify as ’Yes’ if index
test results were inter-
preted without knowl-
edge.
Classify as ’No’ if the
index test results were
interpreted with knowl-
edge.
Classify as ’Unclear’ if it
is unclear whether the re-
sults of the second in-
dex test were interpreted
without knowledge of
the results of the first in-
dex test?
Were all patients in-
cluded in the analysis?
Classify as ’Yes’ if all pa-
tients were included in
the analysis.
Classify as ’No’ is only
some patients were in-
cluded in the analysis.
Classify as ’Unclear’ if it
is unclear whether all pa-
tients were included in
the analysis.
If a threshold was used,
was it prespecified?
Classify as ’Yes’ if the
threshold was prespeci-
fied.
Classify as ’No’ if the
threshold was not pre-
specified.
Classify as ’Unclear’ if
it is unclear whether the
threshold was prespeci-
fied.
Were any conflicts of in-
terest stated?
Classify as ’Yes’ if the
study declared no con-
flict of interest.
Classify as ’No’ if the
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Table 2. Indicators for the assessment of quality (QUADAS-2) (Continued)
study if the study de-
clared a conflict of inter-
est.
Classify as ’Un-
clear’ there was no infor-
mation on conflict of in-
terest.
Risk of bias: High/Low/
Unclear
Could the selection of
patients have introduced
bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
bias?
Could the reference stan-
dard, its conduct, or its
interpretation have in-
troduced bias?





Are there concerns that
the included patients do
not match the review
question?
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
Table 3. Pairwise comparison of diagnostic accuracy
Vital staining Cytology Light-based
Vital staining Sensitivity 0.84 (0.74 to 0.90)
Specificity 0.70 (0.59 to 0.79)
Cytology Likelihood-ratio test
Sensitivity P = 0.23
Specificity P = 0.003
Sensitivity 0.91 (0.81 to 0.96)





Sensitivity P = 0.99
Specificity P = 0.02
Sensitivity 0.91 (0.77 to 0.0.97)
Specificity 0.58 (0.22 to 0.87)
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A P P E N D I C E S
Appendix 1. The Cochrane Oral Health Group Trials Register Search Strategy
An updated search of the Oral Health Group Trials Register was conducted 30 April 2013 using the Cochrane Register of Studies
software and the search strategy below:
#1 ((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or
cheek* or intra-oral* or intraoral* or gum or gums or labial*):ti,ab) AND (INREGISTER)
#2 ((tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas* or malignan* or metasta* or dysplas* or lesion* or ulcer* or
precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus” or leukoplakia or “submucous fibrosis” or “actinic keratosis”
or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or hyperplas* or hyperkerato*):ti,ab) AND (INREGISTER)
#3 ((cytodiagnosis or cytophotometry or “brush biops*” or “oral cdx” or oralcdx or “modified liquid based cytology” or “exfoliat*
cytolog*” or “tolonium chloride” or “toludine b*” or “toluidine b*” or tblue or t-blue or “toludine dye*” or “toludine rins*” or “toludine
stain*” or “toludine wash*” or “toluidine dye*” or “toluidine rins*” or “toluidine stain*” or “toluidine wash*” or luminescence or
fluorescen* or “light emitting diode*”):ti,ab) AND (INREGISTER)
#4 (((blood or saliva) AND (analys* or inspect* or test or examin*)):ti,ab) AND (INREGISTER)
#5 ((“blue spectrum” or LED or luminous or “visual* adjunct*” or vizilite or microlux* or orascoptic or velscope or lumenoscope* or
autofluorescen* or chemilumiescen* or spectrophotometr* or “acetic acid” or acetowhite or “tumor marker*” or “tumour marker*” or
“neoplas* marker*”):ti,ab) AND (INREGISTER)
#6 ((diagnos* AND (exam* or histolog* or check* or screen*)):ti,ab) AND (INREGISTER)
#7 (#1 and #2) AND (INREGISTER)
#8 (#3 or #4 or #5 or #6) AND (INREGISTER)
#9 (#7 and #8) AND (INREGISTER)
A previous search was conducted in June 2011 using the Procite software and the search strategies below:
((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or cheek*
or intra-oral* or intraoral* or gum or gums or labial*) AND (tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas*
or malignan* or metasta* or dysplas* or lesion* or ulcer* or precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus”
or leukoplakia or “submucous fibrosis” or “actinic keratosis” or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or
hyperplas* or hyperkerato*) AND (cytodiagnosis or cytophotometry or “brush biops*” or “oral cdx” or oralcdx or “modified liquid
based cytology” or “exfoliat* cytolog*” or “tolonium chloride” or “toludine b*” or “toluidine b*” or tblue or t-blue or “toludine dye*”
or “toludine rins*” or “toludine stain*” or “toludine wash*” or “toluidine dye*” or “toluidine rins*” or “toluidine stain*” or “toluidine
wash*” or luminescence or fluorescen* or “light emitting diode*”))
((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or cheek*
or intra-oral* or intraoral* or gum or gums or labial*) AND (tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas*
or malignan* or metasta* or dysplas* or lesion* or ulcer* or precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus”
or leukoplakia or “submucous fibrosis” or “actinic keratosis” or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or
hyperplas* or hyperkerato*) AND (“blue spectrum” or LED or luminous or “visual* adjunct*” or vizilite or microlux* or orascoptic
or velscope or lumenoscope* or autofluorescen* or chemilumiescen* or spectrophotometr* or “acetic acid” or acetowhite or “tumor
marker*” or “tumour marker*” or “neoplas* marker*”))
((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or cheek*
or intra-oral* or intraoral* or gum or gums or labial*) AND (tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas*
or malignan* or metasta* or dysplas* or lesion* or ulcer* or precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus”
or leukoplakia or “submucous fibrosis” or “actinic keratosis” or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or
hyperplas* or hyperkerato*) AND (diagno* and (blood or saliva) and (analys* or inspect* or test* or examin*)))
((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or cheek*
or intra-oral* or intraoral* or gum or gums or labial*) AND (tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas*
or malignan* or metasta* or dysplas* or lesion* or ulcer* or precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus”
or leukoplakia or “submucous fibrosis” or “actinic keratosis” or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or
hyperplas* or hyperkerato*) AND (diagnos* AND (exam* or histolog* or check or inspect* or screen*)))
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Appendix 2. Cochrane DTA Register Search Strategy
((oral* or mouth* or bucca* or “oral cavit*” or “oral mucosa” or “mouth mucosa” or lip or lips or tongue* or gingiva* or palat* or cheek*
or intra-oral* or intraoral* or gum or gums or labial*) AND (tumour* or tumor* or cancer* or carcinoma* or carcinogen* or neoplas*
or malignan* or metasta* or dysplas* or lesion* or ulcer* or precancer* or pre-cancer* or premalignan* or precursor* or “lichen planus”
or leukoplakia or “submucous fibrosis” or “actinic keratosis” or candidiasis or erythroplakia or erythroplas* or erythroleukoplakia or
hyperplas* or hyperkerato*)




4. exp Carcinoma, squamous cell/di
5. exp Precancerous conditions/di
6. (tumor$ or tumour$ or cancer$ or carcinoma$ or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or
ulcer$).tw,ot.
7. (pre-cancer$ or precancer$ or premalignan$ or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic
adj2 keratosis) or candidiasis or erythroplakia or erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkeratos$).tw,ot.
8. or/4-7
9. 3 and 8
10. exp Mouth neoplasms/di
11. Lichen Planus, Oral/di
12. Oral submucous fibrosis/di
13. Oral candidiasis/di
14. ((oral$ or mouth$ or bucca$ or “oral cavit$” or (oral adj mucosa$) or (mouth adj mucosa$) or lip or lips or tongue$ or gingiv$
or palat$ or cheek$ or “intra oral$” or intraoral$ or gum or gums or labial$) adj3 (tumor$ or tumour$ or cancer$ or carcinoma$
or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or ulcer$ or pre-cancer$ or precancer$ or premalignan$
or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic adj2 keratosis) or candidiasis or erythroplakia or
erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkerato$)).tw,ot.
15. or/10-14




20. (brush adj3 biops$).tw,ot.
21. (“oral cdx” or oralcdx).tw,ot.
22. (“modified liquid based cytology” or (exfoliat$ adj3 cytolog$)).tw,ot.
23. (brush$ and (cytodiagnosis or cytopathology)).tw,ot.
24. Tolonium chloride/du
25. Coloring agents/du
26. (“tolonium chloride” or “tolu?dine blue” or “tolu?dine b” or tblue or t-blue).tw,ot.




31. exp Luminescent Agents/du
32. Light/du
33. Tomography, Optical Coherence/
34. (visual$ adj5 (“light emitting diode” or “blue spectrum” or LED or luminous$)).tw,ot.
35. (visuali?ation adj3 adjunct$).tw,ot.
36. (vizilite or microlux$ or orascoptic or velscope).tw,ot.
37. lumenoscop$.tw,ot.
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38. ((tumor$ or tumour$ or cancer$ or carcinoma$ or neoplas$ or carcinogen$ or malignan$ or metata$ or lesion$ or ulcer$) adj5
(fluorescen$ or autofluorescen$ or luminescen$ or chemiluminescen$)).tw,ot.
39. (tissue adj3 reflect$).tw,ot.
40. Spectrophotometry/
41. Acetic acid/du
42. (acetic acid adj3 (wash$ or rins$)).tw,ot.
43. acetowhite.tw,ot.
44. Saliva/an, ch
45. Tumor Markers, Biological/an
46. ((“tumo?r marker$” or “neoplas$ marker$”) adj3 (blood or saliva)).tw,ot.




51. ((oral$ or mouth$) adj5 (exam$ or histolog$ or check$ or inspect$)).tw,ot.
52. (visual$ adj3 (exam$ or inspect$ or screen$)).tw,ot.
53. or/17-52
54. 16 and 53




4. exp Squamous cell carcinoma/di
5. exp Precancer/di
6. (tumor$ or tumour$ or cancer$ or carcinoma$ or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or
ulcer$).tw,ot.
7. (pre-cancer$ or precancer$ or premalignan$ or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic adj2
keratosis) or candidiasis or erythroplakia or erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkeratos$).tw,ot.
8. or/4-7
9. 3 and 8
10. exp Mouth tumor/di
11. Lichen planus/di
12. Thrush/di
13. ((oral$ or mouth$ or bucca$ or “oral cavit$” or (oral adj mucosa$) or (mouth adj mucosa$) or lip or lips or tongue$ or gingiv$
or palat$ or cheek$ or “intra oral$” or intraoral$ or gum or gums or labial$) adj3 (tumor$ or tumour$ or cancer$ or carcinoma$
or carcinogen$ or neoplas$ or malignan$ or metasta$ or dysplas$ or lesion$ or ulcer$ or pre-cancer$ or precancer$ or premalignan$
or precursor$ or “lichen planus” or leukoplakia or “submucous fibrosis” or (actinic adj2 keratosis) or candidiasis or erythroplakia or
erythroplas$ or erythroleukoplakia or hyperplas$ or hyperkerato$)).tw,ot.
14. or/10-13
15. 9 or 14
16. Cancer cytodiagnosis/
17. Cytophotometry/
18. (brush adj3 biops$).tw,ot.
19. (“oral cdx” or oralcdx).tw,ot.
20. (“modified liquid based cytology” or (exfoliat$ adj3 cytolog$)).tw,ot.
21. (brush$ and (cytodiagnosis or cytopathology)).tw,ot.
22. Tolonium chloride/
23. Coloring agent/
24. (“tolonium chloride” or “tolu?dine blue” or “tolu?dine b” or tblue or t-blue).tw,ot.
25. (tolu?dine adj6 (dye$ or rins$ or stain$ or wash$)).tw,ot.
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29. exp Luminescent Agents/
30. Light/
31. Tomography, Optical Coherence/
32. (visual$ adj5 (“light emitting diode” or “blue spectrum” or LED or luminous$)).tw,ot.
33. (visuali?ation adj3 adjunct$).tw,ot.
34. (vizilite or microlux$ or orascoptic or velscope).tw,ot.
35. lumenoscop$.tw,ot.
36. ((tumor$ or tumour$ or cancer$ or carcinoma$ or neoplas$ or carcinogen$ or malignan$ or metata$ or lesion$ or ulcer$) adj5
(fluorescen$ or autofluorescen$ or luminescen$ or chemiluminescen$)).tw,ot.
37. (tissue adj3 reflect$).tw,ot.
38. Spectrophotometry/
39. Acetic acid/




44. ((“tumo?r marker$” or “neoplas$ marker$”) adj3 (blood or saliva)).tw,ot.
45. ((analy$ or screen$ or test$ or examin$) adj3 (blood or saliva)).tw,ot.
46. Mass screening/
47. Physical examination/
48. ((oral$ or mouth$) adj5 (diagnos$ or exam$ or histolog$ or check$ or inspect$)).tw,ot.
49. (visual$ adj3 (exam$ or inspect$ or screen$)).tw,ot.
50. or/16-49
51. 15 and 50
Appendix 5. MEDION Search Strategy
Searched using the code C (malignancies), and screened for oral cancer terms.
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